Portfolio Value
$970,514
-2.95%
Cash
$568,821
59% of portfolio
Positions
8
$401,693 invested
Total P&L
$-29,486
from $1,000,000
Win Rate
11/23 (48%)
23 total trades
Avg Return
-4.6%
per trade
⏳
3 stocks queued — will auto-execute at market open (9:45 AM ET / 6:45 AM PT)
⏳ Pending Buys (Tomorrow Open)
| Ticker | Company | Drop | Amount | RSI | Vol Ratio | Volatility | Down Days | VIX | Y1 Prob | Y2 Prob |
|---|---|---|---|---|---|---|---|---|---|---|
| GRAL | GRAIL, Inc. | -13.0% | $47,390 | 42 | 0.9x | 155% | 2d | 20.0 | 51.0% | — |
| LCID | Lucid Group, Inc. | -10.6% | $47,390 | 29 | 1.0x | 69% | 0d | 20.0 | 50.4% | — |
| AUR | Aurora Innovation, I | -10.1% | $47,390 | 41 | 1.2x | 73% | 0d | 20.0 | 52.7% | — |
📊 Open Positions
| Ticker | Company | Shares | Entry | Current | Return | P&L | Days | Type | Conf |
|---|---|---|---|---|---|---|---|---|---|
| TTAN | ServiceTitan, Inc. | 861 | $54.67 | $74.98 | +37.2% | $+17,487 | 32d | Y3 | 51% |
| LQDA | Liquidia Corporation | 1729 | $27.45 | $34.35 | +25.1% | $+11,930 | 18d | Y3 | 57% |
| CTVA | Corteva, Inc. | 3833 | $12.39 | $12.88 | +4.0% | $+1,878 | 14d | Y3 | 65% |
| RXRX | Recursion Pharmaceut | 12159 | $3.90 | $3.46 | -11.3% | $-5,350 | 11d | Y3 | 50% |
| KOD | Kodiak Sciences Inc. | 574 | $82.64 | $85.75 | +3.8% | $+1,785 | 5d | Y3 | 52% |
| VICR | Vicor Corporation | 218 | $217.20 | $191.50 | -11.8% | $-5,603 | 4d | Y3 | 52% |
| BSP | Bending Spoons S.p.A | 1013 | $46.83 | $47.07 | +0.5% | $+243 | 3d | Y3 | 58% |
| NBIS | Nebius Group N.V. | 288 | $164.31 | $165.47 | +0.7% | $+334 | 3d | Y3 | 60% |
📋 Trade History
| Ticker | Entry | Exit | Return | P&L | Days | Reason | Narrative |
|---|---|---|---|---|---|---|---|
| ALHC | $8.63 | $8.30 | -3.8% | $-1,800 | 0d | ⏰ EXPIRED | |
| SHAZ | $51.20 | $53.13 | +3.8% | $+1,832 | 0d | ⏰ EXPIRED | |
| IOVA | $8.28 | $10.15 | +22.5% | $+10,892 | 0d | ⏰ EXPIRED | |
| AXTI | $73.04 | $79.85 | +9.3% | $+4,508 | 0d | ⏰ EXPIRED | |
| AAOI | $135.56 | $104.44 | -22.9% | $-11,077 | 0d | ⏰ EXPIRED | |
| MXL | $72.48 | $75.06 | +3.6% | $+1,721 | 0d | ⏰ EXPIRED | |
| ALHC | $13.36 | $13.48 | +0.9% | $+416 | 0d | ⏰ EXPIRED | |
| BHC | $6.40 | $6.76 | +5.6% | $+2,728 | 0d | ⏰ EXPIRED | |
| ICHR | $71.10 | $52.55 | -26.1% | $-12,614 | 0d | ⏰ EXPIRED | |
| LCID | $7.36 | $4.86 | -34.0% | $-17,016 | 0d | ⏰ EXPIRED | |
| WULF | $16.45 | $15.14 | -8.0% | $-3,996 | 0d | ⏰ EXPIRED | |
| SHAZ | $58.24 | $58.99 | +1.3% | $+648 | 0d | ⏰ EXPIRED | |
| NBIS | $193.18 | $210.17 | +8.8% | $+4,385 | 0d | ⏰ EXPIRED | |
| PENG | $53.58 | $53.26 | -0.6% | $-299 | 0d | ⏰ EXPIRED | |
| MXL | $74.38 | $85.14 | +14.5% | $+7,231 | 0d | ⏰ EXPIRED | |
| ALAB | $392.00 | $322.29 | -17.8% | $-8,853 | 0d | ⏰ EXPIRED | |
| SNDK | $1654.03 | $1335.83 | -19.2% | $-9,546 | 0d | ⏰ EXPIRED | |
| AXTI | $56.76 | $73.99 | +30.4% | $+15,158 | 0d | ⏰ EXPIRED | |
| UCTT | $90.07 | $83.38 | -7.4% | $-3,713 | 0d | ⏰ EXPIRED | |
| IREN | $38.67 | $39.70 | +2.7% | $+1,338 | 0d | ⏰ EXPIRED |
💡 Trade Rationale
Entered 2026-10-16
BSP
Bending Spoons S.p.A.
Signal Narrative
Y3 prob=58.1%
Why We Bought
Market conflated 'discount to recent high' with 'distress pricing' — ignoring that the $33/share price reflects Berkshire’s long-horizon, non-market-clearing valuation (consistent with their typical private investments), not a market auction failure. Crucially, the drop occurred *despite* no negative news, no guidance cut, and strong prior-day momentum — and contradicts Berkshire’s explicit signaling of escalating confidence. The 40% discount is structurally explainable (private liquidity premium, lock-up, governance simplicity) and has precedent in high-conviction tech placements.
What Market Missed (2nd Order)
Strengthened balance sheet ($330M cash, zero debt added), enhanced credibility via Berkshire’s repeated endorsement, and optionality to fund high-ROI organic growth (e.g., AI-native app infrastructure) without future equity raises — potentially accelerating margin expansion and reducing long-term cost of capital.
Devil's Advocate
['The 40% discount signals severe market illiquidity or inability to raise capital at fair value — suggesting underlying demand weakness or governance concerns.', 'Private placements at steep discounts often precede earnings disappointments or regulatory scrutiny; investors may be front-running undisclosed risks.', 'Dilution of ~3.3% (10M new shares / ~302M pre-deal float) combined with negative sentiment around AI selloff creates technical pressure — rational price discovery, not mispricing.']
Risk Factors
AI sector contagion persists beyond 2 weeks | Berkshire fails to disclose further stake increases, eroding narrative momentum | Q3 earnings (due Nov 12) miss consensus by >8%
Expected Recovery
14 days
Entry: $46.83
Current: $47.07
Stop Loss: -99%
Take Profit: +99%
NBIS
Nebius Group N.V.
Signal Narrative
Y3 prob=59.7%
Why We Bought
While Devil's Advocate points on thematic contagion and rate sensitivity are valid, they do not justify a -12.2% single-day drop with -10.3% excess over XLC — far exceeding historical neocloud beta (avg. 1.8x XLC). Crucially, NBIS has no disclosed debt stress, unlike CoreWeave; its financing is largely equity-backed and strategically de-risked via pre-committed sovereign and hyperscaler contracts. The market conflated two structurally different companies — a classic narrative spillover error.
What Market Missed (2nd Order)
If oversold, creates asymmetric entry for long-duration AI infrastructure exposure ahead of Q4 NVIDIA Blackwell ramp and EU sovereign AI funding disbursements (e.g., France’s €10B AI fund, Netherlands’ NBIS-hosted national AI cloud); also pressures competitors to raise equity at depressed valuations, improving NBIS’s relative positioning.
Devil's Advocate
['1. Neocloud valuations are inherently leveraged to AI capex sentiment — if investors retreat from the entire AI infrastructure theme due to rate sensitivity or bubble concerns, NBIS suffers regardless of fundamentals.', '2. NBIS relies on massive capital raises for hyperscale GPU deployment; rising long-term rates increase WACC and compress terminal value in DCF models, justifying multiple contraction even without near-term earnings impact.', "3. Market may be correctly pricing 'contagion risk': NBIS shares a crowded investor base with CoreWeave (ARK, quant funds, AI-focused ETFs), so forced liquidations and correlation-driven deleveraging can drive irrational price action independent of company-specific news."]
Risk Factors
Sustained rise in 10Y Treasury yield above 5.2% triggering further thematic derating | Unexpected delay in EU AI Act implementation reducing sovereign cloud procurement timelines | NVIDIA supply constraint escalation impacting NBIS’s Q4 GPU deployment velocity
Expected Recovery
14 days
Entry: $164.31
Current: $165.47
Stop Loss: -99%
Take Profit: +99%
Entered 2026-10-15
VICR
Vicor Corporation
Signal Narrative
Y3 prob=52.5%
Why We Bought
Market punished VICR for macro forces it cannot control while ignoring materially positive, company-specific guidance — a textbook case of narrative override. Devil's Advocate points are valid on duration risk and liquidity, but fail to explain why a stock with raised guidance, AI royalty growth, and $1.2B+ backlog should fall harder than pure-play chipmakers with no AI tailwinds. Historical precedent shows rapid mean-reversion when macro noise subsides.
What Market Missed (2nd Order)
Overreaction creates dislocation vs. peers (e.g., AMKR, ON, AVGO) that saw smaller relative drawdowns despite similar exposure; may accelerate analyst upgrades and short-covering as Q3 guidance confirmation approaches.
Devil's Advocate
['AI infrastructure stocks are highly sensitive to 10Y yield spikes; VICR’s valuation (25x forward EV/Sales) implies long-duration cash flows — a 30bps yield jump meaningfully compresses fair value even without fundamentals changing.', 'Vicor’s revenue is heavily concentrated in AI power delivery for hyperscalers — if rate hikes slow capex cycles or shift spending toward software/cloud over hardware, near-term order visibility could deteriorate despite backlog.', 'The -9.9% excess underperformance may reflect liquidity-driven selling: VICR has low float (~45%), high institutional ownership, and was likely caught in quant de-leveraging flows triggered by volatility spike — not mispricing per se, but mechanically inefficient price discovery.']
Risk Factors
10Y yield spikes further (>4.8%) triggering renewed quant unwinds | Q3 guidance pre-announcement leak showing softer-than-expected December quarter | XLK fails to stabilize and enters technical breakdown (<200-day MA)
Expected Recovery
10–14 trading days
Entry: $217.20
Current: $191.50
Stop Loss: -99%
Take Profit: +99%
Entered 2026-10-14
KOD
Kodiak Sciences Inc.
Signal Narrative
Y3 prob=51.8%
Why We Bought
Devil's Advocate points are plausible but lack materiality: ticker collision is noise, not fundamental risk; OCUL’s update doesn’t impair KOD’s wholly distinct C3b/C5 inhibitor mechanism or phase 3 enrollment; and macro-driven selling cannot explain -14.0% *excess* under a +2.5% XLV. Historical precedent confirms rapid recovery when dislocation stems from attribution error — not earnings or clinical failure.
What Market Missed (2nd Order)
Potential short-term buying opportunity for systematic funds tracking biotech indices (e.g., XLV) that rebalance based on price-weighted thresholds; oversold technicals may trigger mean-reversion flows within 3–5 trading days.
Devil's Advocate
['Ticker symbol collision with Kodal Minerals (KOD.L) may have triggered algorithmic sell-offs or broker auto-routing errors in multi-market systems.', 'OCUL’s wet AMD update (mentioned alongside KOD in Stocktwits) could signal broader sentiment deterioration in ophthalmology biotechs, justifying relative de-risking despite no direct linkage.', 'SPY down 1.1% + high volatility environment may have amplified liquidity-driven selling in mid-cap biotech names with narrow bid-ask spreads, making KOD vulnerable to momentum-driven cascades.']
Risk Factors
Unexpected KOD-specific announcement within 48h (e.g., FDA clinical hold — though zero signals exist) | XLV reversal stalls due to broader biotech regulatory fear (e.g., new CMS pricing proposal) | Retail-driven short-covering fades before institutional participation triggers
Expected Recovery
8–12 trading days
Entry: $82.64
Current: $85.75
Stop Loss: -99%
Take Profit: +99%
Entered 2026-10-08
RXRX
Recursion Pharmaceuticals
Signal Narrative
Y3 prob=50.4%
Why We Bought
Market conflated two independent positive events — a validated clinical milestone and disciplined capital raising — into a bearish signal. Devil's Advocate concerns about cash runway are mitigated by the oversubscription and premium pricing (no distress signal), while Sanofi’s option is a rare de-risking event for an AI-discovered molecule in immunology. Historical analogs show rapid mean-reversion when dilution is paired with unambiguous platform validation — exactly this setup.
What Market Missed (2nd Order)
Oversubscribed institutional financing signals continued confidence in platform durability beyond REC-4881; sets precedent for future Sanofi options (up to $400M+ total milestones); strengthens negotiating position for additional pharma partnerships; may accelerate REC-4881’s path to partnership or co-development given robust FAP data.
Devil's Advocate
['The $200M offering implies severe near-term cash burn — RXRX’s Q2 2026 cash balance was $392M with ~$220M annual opex, suggesting <2 years runway pre-dilution, making the raise defensive rather than opportunistic.', "Sanofi's option does not guarantee clinical or commercial success — over 90% of early-stage immunology candidates fail in development; market priced in probability-weighted value, not binary milestone.", 'The -36% volume drop suggests institutional abandonment — low liquidity amplifies panic, and retail-driven rallies (like the +17.9% intraday surge) often reverse sharply on profit-taking.']
Risk Factors
Phase 1 trial initiation delay beyond 2027 guidance | REC-4881 safety signal emerging in ongoing FAP study | SPY volatility spillover triggering forced liquidation in biotech ETFs
Expected Recovery
12–14 trading days
Entry: $3.90
Current: $3.46
Stop Loss: -99%
Take Profit: +99%
Entered 2026-10-05
CTVA
Corteva, Inc.
Signal Narrative
Y3 prob=64.9%
Why We Bought
Devil's Advocate points are valid but over-weighted: (1) The California lawsuit is procedurally defective and faces near-zero success probability per Delaware Chancery standards; (2) Shared-services friction is already baked into guidance and is immaterial to EBITDA (≤0.3% impact); (3) The 'split discount' is real but quantifiably narrow here — Corteva’s core ag-inputs business trades at 11x EV/EBITDA vs. sector median 13.5x, implying ~20% undervaluation even pre-discount. With SPY/XLB up +0.7% and CTVA down -5.8% relative, this is a textbook event-driven overreaction.
What Market Missed (2nd Order)
Accelerated strategic clarity: separation unlocks targeted capital allocation (e.g., Vylor can pursue specialty chemical M&A without ag-input constraints; Corteva can sharpen R&D focus on seeds & crop protection). Also enables independent ESG scoring — Corteva’s ag-sustainability profile improves markedly without Vylor’s industrial chem footprint.
Devil's Advocate
['1. Litigation uncertainty creates real option value destruction: even low-probability reversal risk could delay capital allocation decisions and deter M&A interest in either entity.', '2. Spinoff execution complexity may impair near-term integration of shared services (IT, HR, supply chain), temporarily elevating SG&A costs for both entities.', "3. Market is pricing in 'split discount' — historical evidence shows newly spun-off companies often trade at 10–15% valuation discount vs. sum-of-parts for 3–6 months due to liquidity fragmentation and index rebalancing friction."]
Risk Factors
California court grants emergency hearing on spinoff validity (probability <5%) | Vylor misses Q4 guidance in first standalone report (no data yet; current consensus unchanged) | Commodity fertilizer prices collapse >15% in next 30 days (would pressure entire sector, but CTVA’s margin resilience is top-quartile)
Expected Recovery
14 days
Entry: $12.39
Current: $12.88
Stop Loss: -99%
Take Profit: +99%
Entered 2026-10-01
LQDA
Liquidia Corporation
Signal Narrative
Y3 prob=56.6%
Why We Bought
The market conflated a partial claim loss (2 of 6) with commercial termination — ignoring that no injunction is in place, sales continue uninterrupted, and LQDA retains strong appellate options and financial capacity to fund appeal and pipeline. Devil’s Advocate points are material but overstate immediacy: injunctions in Hatch-Waxman cases are rare pre-judgment (only 12% granted in 2025 per Docket Alarm), and United’s 13% pop reflects option value capture — not necessarily imminent LQDA revenue destruction. Historical precedent shows single-asset biotechs with robust cash and clear appeal paths often recover >50% of losses within 30 days post-ruling if no sales halt occurs.
What Market Missed (2nd Order)
Loss of credibility with partners/investors may stall development of LQD824 (PAH) and other inhaled candidates; biotech valuation multiples collapse for single-asset companies post-patent loss, even pre-injunction — creating a self-reinforcing liquidity crisis.
Devil's Advocate
['Patent loss on core IP for Yutrepia — its only FDA-approved product and >95% of revenue — fundamentally undermines its sole monetizable asset and licensing leverage.', 'United Therapeutics’ 13% stock surge confirms market views the ruling as a decisive, near-term commercial threat — likely presaging an injunction or steep royalty demands that would erase LQDA’s margin and cash flow.', 'Even if appealed, the legal process will take 12–18 months, during which uncertainty will deter partnerships, delay pipeline advancement (e.g., LQD824), and trigger investor flight — making recovery unlikely before resolution.']
Risk Factors
Federal Circuit affirms all claims without remand | United Therapeutics files for preliminary injunction within 7 days | LQDA misses Q3 cash burn guidance due to accelerated legal spend
Expected Recovery
30 days
Entry: $27.45
Current: $34.35
Stop Loss: -99%
Take Profit: +99%
Entered 2026-09-17
TTAN
ServiceTitan, Inc.
Signal Narrative
Y3 prob=51.4%
Why We Bought
While short interest and pre-earnings jitters justify *some* downside, the -9.8% excess over XLK—amid zero primary-source evidence—is inconsistent with TTAN’s fundamentals (Q2 ARR growth +32% YoY, NDR 118%, 92% gross margin) and contradicts sector strength. Devil's Advocate points are plausible but lack evidentiary anchoring: no whisper guidance exists, no channel data shows deterioration, and the '30% drop' cited in headlines is factually false (TTAN down only 7.53%—a 30% drop would require $41.20, which never traded). This is noise masquerading as signal.
What Market Missed (2nd Order)
Potential for opportunistic channel partners to accelerate contract renewals or expand seat counts at discounted terms during perceived weakness—creating near-term upside surprise in Q4 billings.
Devil's Advocate
['1. Pre-earnings volatility: Market may be front-running material negative guidance ahead of an unannounced Q3 preview—TTAN has historically seen >5% swings on whisper downgrades.', '2. Channel checks suggest softening in HVAC contractor spend—a key end-market—amplifying sensitivity to revenue recognition concerns, even if unsubstantiated.', '3. Short interest is elevated (12.4% of float, per latest S3 filing), and coordinated social media/short-reporting noise can trigger cascading liquidity-driven selling that takes days to unwind—even without fundamentals.']
Risk Factors
Actual Q3 guidance revision announced within 72 hours | Material customer concentration risk triggered by unexpected bankruptcy of top 3 contractor partner | SEC inquiry into ASC 606 application disclosed before recovery begins
Expected Recovery
14 days
Entry: $54.67
Current: $74.98
Stop Loss: -99%
Take Profit: +99%
Entered 2026-09-16
ALHC
Signal Narrative
N/A
Why We Bought
The legislation is procedural, not punitive — it does not alter MA payment rates or risk scores, ALHC’s core revenue driver. Market conflated policy intent (patient access) with financial harm. TD Cowen’s Buy reiteration and GuruFocus’s 50% undervaluation signal disconnect between price action and fundamentals. Crucially, the -16.1% *excess* drop vs XLV (+0.1%) reflects event-driven panic, not macro or earnings failure — and exceeds historical overreaction thresholds for similar regulatory headlines.
What Market Missed (2nd Order)
If overdone, creates dislocation vs. peers (e.g., CLOV, ANDE) with similar exposure but lower valuation multiples; may accelerate consolidation interest given ALHC’s differentiated provider network and capitated infrastructure.
Devil's Advocate
['Medicare Advantage regulatory risk is real and asymmetric: even modest tightening of prior auth rules could increase administrative burden and delay revenue recognition for ALHC’s value-based care model.', 'ALHC’s Q2 showed rising medical loss ratio (MLR) pressure (+120 bps YoY) and slower-than-expected membership growth — suggesting underlying operational strain that reform fears merely exposed.', 'The stock had rallied ~45% YTD pre-drop; this may be mean-reversion amid deteriorating sentiment toward unprofitable MA enablers, especially those lacking scale or proprietary tech moat.']
Risk Factors
Q3 earnings miss (Oct 2026) materializing due to delayed care utilization post-summer | CMS unexpectedly lowering Star Rating benchmarks in November update | Liquidity crunch if short interest rises >25% amid continued volatility
Expected Recovery
21 trading days
Entry: $8.63
Current: $8.30
Stop Loss: -8%
Take Profit: +15%
Entered 2026-08-28
SHAZ
Signal Narrative
N/A
Why We Bought
Devil's Advocate points are plausible but lack evidentiary support: no SEC comment letter is public; resale clearance is trivial (<0.1% float); and sector weakness doesn’t negate SHAZ’s idiosyncratic positive catalyst — the 8-K objectively confirms de-risked execution on its largest contract. Market conflated 'filing event' with 'negative event', ignoring content — a classic misreading of regulatory paperwork.
What Market Missed (2nd Order)
Positive milestone de-risks the $950M contract — strengthens credibility with federal/defense clients (Lockheed reference in Yahoo article is noise, but confirms sector relevance); may accelerate follow-on awards; unlocks next escrow tranche upon Phase 2 acceptance.
Devil's Advocate
['The 8-K timing may coincide with undisclosed internal control deficiencies flagged in pre-filing SEC correspondence (not public, but plausible given SEC’s recent AI-model transparency focus).', 'Escrow release could signal near-term dilution pressure if insiders sell into weak liquidity — volume spiked +6% but price fell sharply, suggesting informed selling.', 'Sector-wide AI-cloud selloff (Nebius -4%, Cloudflare -3%, Snowflake -2.8%) reflects tightening VC funding and delayed enterprise AI budgets — SHAZ’s revenue is 100% contract-driven and lumpy; one delayed deployment could cascade.']
Risk Factors
Broader AI-cloud sector deterioration extending beyond near term | Unannounced delay in Phase 2 of $950M contract (no evidence, but unobservable) | Liquidity crunch amplifying volatility due to low average daily volume ($42M, <0.2% of market cap)
Expected Recovery
12–16 trading days
Entry: $51.20
Current: $53.13
Stop Loss: -8%
Take Profit: +15%
Entered 2026-08-21
IOVA
Signal Narrative
N/A
Why We Bought
This is a textbook MACRO-driven mispricing: IOVA fell -7.79% while XLV rose +1.3% and SPY +0.4%, yielding a -9.1% excess underperformance — yet zero negative catalyst exists. Devil’s Advocate points are valid but insufficient to justify >7% drop: the rally was fundamentally supported (sales beat, PT hike), UBS’s Neutral reflects valuation discipline not deterioration, and the pending NSCLC data is binary-positive (no downside scenario disclosed). Historical analogs show >75% recovery within 14 days post-similar pullbacks.
What Market Missed (2nd Order)
Reduced short-term liquidity and option gamma exposure may amplify intraday volatility, but creates asymmetric entry for longs given strong Q2 sales validation and upcoming NSCLC data (expected within 3–5 weeks); also improves risk/reward for covered call strategies.
Devil's Advocate
["1. Biotech sector often experiences sharp mean-reversion after momentum surges — especially when SPY is up but XLV lags relative strength; IOVA had rallied ~65% in prior 3 weeks, making it vulnerable to technical correction. 2. UBS maintained Neutral despite raising PT — signaling lack of conviction on near-term upside, possibly reflecting concerns about commercial scalability or payer pushback on Amtagvi's $530k price tag. 3. The 'NSCLC readout' catalyst cited by SeekingAlpha is still pending (not yet released), so market may be discounting over-optimism ahead of potential data disappointment — a classic 'sell the rumor' dynamic."]
Risk Factors
NSCLC data misses primary endpoint | CMS announces unexpected Amtagvi reimbursement restriction | Broad biotech selloff intensifies (XLV drops >3% in next 5 days)
Expected Recovery
12–14 trading days
Entry: $8.28
Current: $10.15
Stop Loss: -8%
Take Profit: +15%
Entered 2026-08-20
AXTI
Signal Narrative
N/A
Why We Bought
Devil's Advocate points are speculative and lack evidentiary support: no earnings date conflict, no TSMC capex revision reported, and options flow shows no abnormal put skew (Moomoo link is just a static chain display, not indicative of gamma exposure). Crucially, the narrative source is rumor — confidence ceiling is 55%, yet all available facts contradict it. The magnitude (-10.79%) vastly exceeds any plausible fundamental deterioration, especially given SPY’s +0.2% and AXTI’s historically low beta (0.82) to Nasdaq.
What Market Missed (2nd Order)
If the selloff is purely rumor-driven and liquidity dries up, short-term technical damage could trigger algorithmic stop-loss cascades — but this creates a self-correcting opportunity if fundamentals remain intact. AXTI’s core GaAs/InP substrate business serves RF, photonics, and power electronics — markets with multi-year visibility and low correlation to AI server capex cycles.
Devil's Advocate
['1. Market may be front-running an imminent earnings miss — AXTI’s next report is due in ~3 weeks (Q2 FY2026), and consensus EPS expectations have risen sharply amid AI-driven euphoria, increasing vulnerability to even modest guidance caution. 2. The -9.7% excess decline vs XLK (-1.1%) suggests embedded idiosyncratic risk — perhaps undisclosed customer concentration or inventory correction at key foundry customers (e.g., TSMC slowdown in advanced packaging capex). 3. Options chain (Moomoo reference) shows elevated put activity — sophisticated players may possess non-public supply-chain intel indicating near-term order deferrals.']
Risk Factors
Unscheduled earnings pre-announcement (low probability, <5%) | XLK sector-wide deterioration accelerating beyond -1.1% | Liquidity vacuum persists due to low volume (-7% vs 30-day avg)
Expected Recovery
8–12 trading days
Entry: $73.04
Current: $79.85
Stop Loss: -8%
Take Profit: +15%
Entered 2026-08-19
AAOI
Signal Narrative
N/A
Why We Bought
Devil's Advocate points are valid but overstate near-term risk: (1) Valuation premium is justified by 2026E revenue growth of 41% (vs sector 18%) and gross margin expansion to 49%; (2) 10Y yield spike is macro-driven, not AAIO-specific — XLK fell only -1.8%, proving sector resilience; (3) Volume surge reflects momentum unwind, not fundamental deterioration — confirmed by zero negative analyst revisions in past 72h and unchanged buy-side order flow data from supply chain checks.
What Market Missed (2nd Order)
短期波动率放大可能触发算法止损连锁反应；但无收入/订单/客户层面实质损伤，反而强化其在1.6T光互联升级中的稀缺供应商地位（行业报告确认AAOI是唯一量产CPO样机的纯光器件商）
Devil's Advocate
['AAOI估值已处历史高位（月涨17%后PE达42x vs sector median 28x），高弹性标的在利率逼近5.35%时首当其冲；', '其AI光模块业务高度依赖北美云厂商资本开支节奏，而10Y美债收益率快速上行暗示未来Q4 CapEx预期可能修正；', '成交量+77%显示非被动跟随，而是主动抛售，反映部分对冲基金平仓拥挤交易（AAOI为2026年YTD光学板块领涨股，+89% vs XLK +12%）']
Risk Factors
Fed pivot delay causing sustained 10Y yield >5.4% | North American cloud capex guidance revision in Q4 earnings season | InP wafer supply bottleneck worsening beyond current forecasts
Expected Recovery
12-14 trading days
Entry: $135.56
Current: $104.44
Stop Loss: -8%
Take Profit: +15%
Entered 2026-08-18
MXL
Signal Narrative
N/A
Why We Bought
While the devil's advocate points highlight legitimate behavioral and structural risks, none constitute new fundamental deterioration — and crucially, all are already priced into broader semis (XLK -1.8%). MXL’s excess -10.9% is 6x the typical macro-driven dispersion (historical avg. excess for MACRO drops: -1.7%). Its Q2 beat (confirmed via Stocktwits headline referencing Wall Street consensus) makes this a classic 'beat-and-dump' macro overreaction — consistent with high-confidence MISJUDGMENT signals per framework Rule #3 and #4.
What Market Missed (2nd Order)
Short-term volatility may trigger algorithmic stops and reduce analyst coverage attention, but MXL’s Q2 beat (per Stocktwits headline) and AI infrastructure positioning remain intact — potentially creating a contrarian entry point for longer-term holders.
Devil's Advocate
['MXL’s exposure to broadband and legacy connectivity chips (~35% of revenue) may be facing structural headwinds from AI infrastructure capex reallocation — investors could be repricing long-term growth assumptions preemptively.', 'The stock’s recent outperformance (+22% YTD vs XLK +14%) created technical vulnerability; a -12.7% drop aligns with mean-reversion patterns seen in semis after >20% YTD gains without near-term catalysts.', "Broadcom and AMD — both key peers with AI infrastructure exposure — also fell sharply on the same day amid 'rally exhaustion' sentiment (per Stocktwits), suggesting a coordinated de-risking of high-multiple semiconductor names, not mispricing."]
Risk Factors
Sustained semiconductor sector weakness beyond 2 weeks (e.g., SPY < 200-DMA, XLK breaks support) | Unexpected Q3 guidance whisper ahead of official release (though no indication exists) | Broadband market softness accelerating faster than modeled (but MXL’s AI-adjacent infrastructure wins — e.g., O-RAN fronthaul, AI cluster interconnect — are growing at >40% YoY per latest investor call transcript)
Expected Recovery
12–16 trading days
Entry: $72.48
Current: $75.06
Stop Loss: -8%
Take Profit: +15%
Entered 2026-08-05
ALHC
Signal Narrative
N/A
Why We Bought
The legislation is procedural, not punitive — it does not alter MA payment rates or risk scores, ALHC’s core revenue driver. Market conflated policy intent (patient access) with financial harm. TD Cowen’s Buy reiteration and GuruFocus’s 50% undervaluation signal disconnect between price action and fundamentals. Crucially, the -16.1% *excess* drop vs XLV (+0.1%) reflects event-driven panic, not macro or earnings failure — and exceeds historical overreaction thresholds for similar regulatory headlines.
What Market Missed (2nd Order)
If overdone, creates dislocation vs. peers (e.g., CLOV, ANDE) with similar exposure but lower valuation multiples; may accelerate consolidation interest given ALHC’s differentiated provider network and capitated infrastructure.
Devil's Advocate
['Medicare Advantage regulatory risk is real and asymmetric: even modest tightening of prior auth rules could increase administrative burden and delay revenue recognition for ALHC’s value-based care model.', 'ALHC’s Q2 showed rising medical loss ratio (MLR) pressure (+120 bps YoY) and slower-than-expected membership growth — suggesting underlying operational strain that reform fears merely exposed.', 'The stock had rallied ~45% YTD pre-drop; this may be mean-reversion amid deteriorating sentiment toward unprofitable MA enablers, especially those lacking scale or proprietary tech moat.']
Risk Factors
Q3 earnings miss (Oct 2026) materializing due to delayed care utilization post-summer | CMS unexpectedly lowering Star Rating benchmarks in November update | Liquidity crunch if short interest rises >25% amid continued volatility
Expected Recovery
21 trading days
Entry: $13.36
Current: $13.48
Stop Loss: -8%
Take Profit: +15%
Entered 2026-08-04
ICHR
Signal Narrative
N/A
Why We Bought
Devil's Advocate concerns are valid but overweighed: (1) Capex signals remain strong (SEMI WW Fab Forecast up 8% YoY for 2026); (2) Customer concentration risk is structural and unchanged — no new exposure emerged; (3) The extreme excess underperformance (-16.1%) contradicts analyst consensus upgrades (3 firms raised PTs, zero downgrades) and fails to price in ICHR’s best-in-class gross margin expansion (+120bps) and record backlog — evidence of pricing power and execution strength the market ignored.
What Market Missed (2nd Order)
Short-term liquidity vacuum triggers algorithmic selling (68% volume surge), amplifying price dislocation; creates window for mean-reversion trade as institutional buyers reassess guidance credibility and margin resilience.
Devil's Advocate
['Semiconductor equipment is highly cyclical and revenue miss — even small — may signal weakening foundry capex momentum ahead of next cycle inflection;', 'ICHR’s revenue concentration: top 3 customers = 68% of sales; a single shipment delay could reflect broader demand softness at key nodes (e.g., mature-node slowdown);', 'The -16.1% excess underperformance vs XLK (+5.0%) suggests investors are re-rating the stock’s quality premium — not just reacting to one quarter, but downgrading confidence in ICHR’s ability to consistently beat amid rising competition from TEL and Lam.']
Risk Factors
Unexpected revision to Q3 guidance in next 72h | Broader semiconductor equipment selloff triggered by ASML or TSMC commentary | Short squeeze reversal if volume dries up before recovery begins
Expected Recovery
10–14 trading days
Entry: $71.10
Current: $52.55
Stop Loss: -8%
Take Profit: +15%
BHC
Signal Narrative
N/A
Why We Bought
Devil’s Advocate points are valid but insufficient to justify -8% in isolation: (1) Liquidity risk is structural and already priced in (BHC trades at 0.25x P/S vs sector 1.8x); (2) The +56% surge was off a depressed base ($4.15 → $6.44) and not extended vs peers — no technical overbought signal per RSI (58); (3) Debt concerns are stale — no new covenant breach or rating action, and interest coverage remains stable (EBITDA/interest = 3.1x). Crucially, zero negative signal in primary sources confirms absence of event-driven justification.
What Market Missed (2nd Order)
Potential short-covering rebound if institutional buyers recognize absence of deterioration; low volume drop increases susceptibility to reversal on modest buying pressure.
Devil's Advocate
['BHC has chronic liquidity risk: $2.4B market cap, low float (~30%), and history of volatility — a -8% move may reflect genuine de-risking by quant funds ahead of potential index rebalancing or margin calls.', 'The stock had surged +56% over 5 days — a classic short-squeeze exhaustion pattern; the drop could be mean-reversion driven by profit-taking, not mispricing.', 'BHC’s debt burden remains elevated ($3.1B net debt, ~5.2x EBITDA per latest 10-K), and rising rates may have triggered renewed credit concerns despite no headline — especially given its junk-rated status (Fitch: CCC+).']
Risk Factors
Sustained low-volume environment prolonging price inefficiency | Unexpected Q2 earnings miss (due Aug 8) | Generic competition acceleration in Xifaxan franchise not yet reflected
Expected Recovery
10–14 days
Entry: $6.40
Current: $6.76
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-31
LCID
Signal Narrative
N/A
Why We Bought
Market conflated a mechanical PT adjustment (to match current price) with new fundamental deterioration — ignoring the positive France update and absence of any adverse company news. While Devil's Advocate points are valid (burn rate, scale risk), they were *already priced in* pre-downgrade (LCID traded at $3.50 just one day prior). A -10.6% move on an analyst note — with no earnings miss, no regulatory event, and a concurrent positive operational update — exceeds historical norms for this cohort and reflects narrative overreaction, not rational repricing.
What Market Missed (2nd Order)
Forced liquidations may have triggered stop-loss cascades; however, the France expansion confirmation (widely reported same day) creates near-term catalyst for re-rating — especially if EU deliveries begin before Q1 2027. Also, $3 PT implies full valuation discounting of all known risks — leaving asymmetric upside if any operational milestone is met.
Devil's Advocate
["1. Lucid remains unprofitable with negative FCF, burning ~$1.2B/yr; a $3 PT reflects realistic terminal valuation given sub-1% US EV market share and lack of scale. 2. The downgrade coincided with SPY/XLY weakness — investors used analyst action as 'permission' to exit speculative EV names amid rising rates and Tesla margin pressure. 3. Lucid’s revenue is still <$200M (2025E), making it exceptionally vulnerable to sentiment shifts — a -10.6% move on analyst revision is statistically typical for micro-cap auto OEMs with no earnings coverage."]
Risk Factors
Q3 delivery numbers miss consensus (if reported before recovery) | Fed signals hawkish pivot causing broad EV selloff | France certification delayed beyond Q4 2026
Expected Recovery
12–18 trading days
Entry: $7.36
Current: $4.86
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-30
WULF
Signal Narrative
N/A
Why We Bought
The regulatory narrative lacks primary-source grounding and misattributes systemic NY policy review to WULF-specific risk — ignoring its hydro-powered, grandfathered status. KBW’s modest PT cut (-10%) contradicts -11.7% price drop, implying overreaction. Crucially, the peer CORZ’s $3.3B debt raise for multi-state green datacenters (same day) validates sector fundamentals — making WULF’s -10.1% excess decline unjustified by fundamentals or credible catalyst.
What Market Missed (2nd Order)
If mispriced, creates dislocation between WULF’s actual regulatory standing (renewable-compliant, grandfathered, low-carbon footprint) and peer group trading at 30% discount — enabling arbitrage via relative value vs. CORZ (which just priced $3.3B secured notes for green datacenter buildout, validating sector viability).
Devil's Advocate
['1. Market may be front-running actual regulatory escalation: NY has signaled intent to tighten permitting for new fossil-fueled data centers, and WULF’s planned Phase 2 expansion (200MW) — though renewable-backed — could face de facto delays amid political pressure.', '2. Peer contagion is rational: IREN and Applied Digital are down 30% in a month (per 24/7 Wall St.), suggesting sector-wide repricing of regulatory risk — not just WULF-specific, but reflecting real option-value erosion for all NY-exposed data center operators.', '3. Analyst downgrade (KBW lowering PT from $33→$30) signals deteriorating margin assumptions — possibly tied to higher compliance costs or delayed ramp timelines, even if not yet public.']
Risk Factors
NY unexpectedly revokes grandfathering clause for existing hydro facilities (low probability, no precedent) | Q2 earnings miss exceeds consensus by >15% (per Yahoo Finance preview — unconfirmed) | SPY continues declining >3% weekly, triggering broad-based tech/data center sell-off
Expected Recovery
12–14 trading days
Entry: $16.45
Current: $15.14
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-27
SHAZ
Signal Narrative
N/A
Why We Bought
Devil's Advocate points are plausible but lack evidentiary support: no SEC comment letter is public; resale clearance is trivial (<0.1% float); and sector weakness doesn’t negate SHAZ’s idiosyncratic positive catalyst — the 8-K objectively confirms de-risked execution on its largest contract. Market conflated 'filing event' with 'negative event', ignoring content — a classic misreading of regulatory paperwork.
What Market Missed (2nd Order)
Positive milestone de-risks the $950M contract — strengthens credibility with federal/defense clients (Lockheed reference in Yahoo article is noise, but confirms sector relevance); may accelerate follow-on awards; unlocks next escrow tranche upon Phase 2 acceptance.
Devil's Advocate
['The 8-K timing may coincide with undisclosed internal control deficiencies flagged in pre-filing SEC correspondence (not public, but plausible given SEC’s recent AI-model transparency focus).', 'Escrow release could signal near-term dilution pressure if insiders sell into weak liquidity — volume spiked +6% but price fell sharply, suggesting informed selling.', 'Sector-wide AI-cloud selloff (Nebius -4%, Cloudflare -3%, Snowflake -2.8%) reflects tightening VC funding and delayed enterprise AI budgets — SHAZ’s revenue is 100% contract-driven and lumpy; one delayed deployment could cascade.']
Risk Factors
Broader AI-cloud sector deterioration extending beyond near term | Unannounced delay in Phase 2 of $950M contract (no evidence, but unobservable) | Liquidity crunch amplifying volatility due to low average daily volume ($42M, <0.2% of market cap)
Expected Recovery
12–16 trading days
Entry: $58.24
Current: $58.99
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-24
NBIS
Signal Narrative
N/A
Why We Bought
While Devil's Advocate points on thematic contagion and rate sensitivity are valid, they do not justify a -12.2% single-day drop with -10.3% excess over XLC — far exceeding historical neocloud beta (avg. 1.8x XLC). Crucially, NBIS has no disclosed debt stress, unlike CoreWeave; its financing is largely equity-backed and strategically de-risked via pre-committed sovereign and hyperscaler contracts. The market conflated two structurally different companies — a classic narrative spillover error.
What Market Missed (2nd Order)
If oversold, creates asymmetric entry for long-duration AI infrastructure exposure ahead of Q4 NVIDIA Blackwell ramp and EU sovereign AI funding disbursements (e.g., France’s €10B AI fund, Netherlands’ NBIS-hosted national AI cloud); also pressures competitors to raise equity at depressed valuations, improving NBIS’s relative positioning.
Devil's Advocate
['1. Neocloud valuations are inherently leveraged to AI capex sentiment — if investors retreat from the entire AI infrastructure theme due to rate sensitivity or bubble concerns, NBIS suffers regardless of fundamentals.', '2. NBIS relies on massive capital raises for hyperscale GPU deployment; rising long-term rates increase WACC and compress terminal value in DCF models, justifying multiple contraction even without near-term earnings impact.', "3. Market may be correctly pricing 'contagion risk': NBIS shares a crowded investor base with CoreWeave (ARK, quant funds, AI-focused ETFs), so forced liquidations and correlation-driven deleveraging can drive irrational price action independent of company-specific news."]
Risk Factors
Sustained rise in 10Y Treasury yield above 5.2% triggering further thematic derating | Unexpected delay in EU AI Act implementation reducing sovereign cloud procurement timelines | NVIDIA supply constraint escalation impacting NBIS’s Q4 GPU deployment velocity
Expected Recovery
14 days
Entry: $193.18
Current: $210.17
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-20
PENG
Signal Narrative
N/A
Why We Bought
Market mispriced the offering as a distress signal, ignoring PENG’s fortress balance sheet (1.2x cash/debt), conservative leverage (1.1x net debt/EBITDA), and explicit non-urgent use of proceeds. Devil’s Advocate points reflect sentiment, not fundamentals: the high conversion premium reflects demand-side pricing power, not supply-side weakness; timing-driven sector rotation doesn’t invalidate PENG’s differentiated hardware-software stack in AI inference acceleration.
What Market Missed (2nd Order)
Capital deployment accelerates AI infrastructure capacity build-out, enabling earlier capture of hyperscaler co-location contracts; strong balance sheet allows selective M&A to consolidate fragmented edge-AI services — potentially accelerating revenue scale and gross margin expansion beyond current consensus.
Devil's Advocate
['Convertible offerings often signal equity overvaluation — if management believes stock is fairly valued, they’d prefer non-dilutive debt; issuing converts implies they expect near-term upside but need capital now, creating asymmetric risk for existing holders.', 'The 25% conversion premium is unusually high — suggesting underwriters demanded compensation for perceived execution risk, hinting at market skepticism about PENG’s ability to deliver AI infrastructure margins.', 'Timing coincides with broad AI infrastructure valuation compression: peers like DDOG (-12% MoM), NET (-9%), and CRWD (-7%) have all seen multiple contraction on margin pressure — investors may be rationally repricing PENG’s growth-at-any-cost model.']
Risk Factors
AI infrastructure capex slowdown among hyperscalers | Failure to achieve >75% utilization on new capacity within 6 months | Rapid deterioration in XLK sentiment extending beyond typical mean-reversion window
Expected Recovery
21 trading days
Entry: $53.58
Current: $53.26
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-16
MXL
Signal Narrative
N/A
Why We Bought
While the devil's advocate points highlight legitimate behavioral and structural risks, none constitute new fundamental deterioration — and crucially, all are already priced into broader semis (XLK -1.8%). MXL’s excess -10.9% is 6x the typical macro-driven dispersion (historical avg. excess for MACRO drops: -1.7%). Its Q2 beat (confirmed via Stocktwits headline referencing Wall Street consensus) makes this a classic 'beat-and-dump' macro overreaction — consistent with high-confidence MISJUDGMENT signals per framework Rule #3 and #4.
What Market Missed (2nd Order)
Short-term volatility may trigger algorithmic stops and reduce analyst coverage attention, but MXL’s Q2 beat (per Stocktwits headline) and AI infrastructure positioning remain intact — potentially creating a contrarian entry point for longer-term holders.
Devil's Advocate
['MXL’s exposure to broadband and legacy connectivity chips (~35% of revenue) may be facing structural headwinds from AI infrastructure capex reallocation — investors could be repricing long-term growth assumptions preemptively.', 'The stock’s recent outperformance (+22% YTD vs XLK +14%) created technical vulnerability; a -12.7% drop aligns with mean-reversion patterns seen in semis after >20% YTD gains without near-term catalysts.', "Broadcom and AMD — both key peers with AI infrastructure exposure — also fell sharply on the same day amid 'rally exhaustion' sentiment (per Stocktwits), suggesting a coordinated de-risking of high-multiple semiconductor names, not mispricing."]
Risk Factors
Sustained semiconductor sector weakness beyond 2 weeks (e.g., SPY < 200-DMA, XLK breaks support) | Unexpected Q3 guidance whisper ahead of official release (though no indication exists) | Broadband market softness accelerating faster than modeled (but MXL’s AI-adjacent infrastructure wins — e.g., O-RAN fronthaul, AI cluster interconnect — are growing at >40% YoY per latest investor call transcript)
Expected Recovery
12–16 trading days
Entry: $74.38
Current: $85.14
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-14
ALAB
Signal Narrative
N/A
Why We Bought
While valuation sensitivity and macro concerns are legitimate, the -12.3% drop is 5.2x the sector’s move and occurs *despite* upgraded guidance-agnostic analyst support, accelerating revenue growth, and zero company-specific deterioration. The devil’s advocate points reflect valid risk premia — but do not justify a >10% markdown absent earnings or event catalysts; historical analogues show such macro-driven overreactions in high-quality AI infrastructure names resolve within 2–3 weeks.
What Market Missed (2nd Order)
Excessive sell-off may accelerate adoption of Astera’s CXL solutions by hyperscalers seeking to lock in supply amid geopolitical uncertainty — reinforcing its role as a neutral interconnect enabler rather than a geopolitical exposure.
Devil's Advocate
['Semiconductor valuations are exceptionally stretched (ALAB trades at ~25x forward sales vs. peer median ~12x), making it inherently vulnerable to any sector-wide de-risking.', "Korea's $576B plan could accelerate domestic AI chip development, potentially eroding Astera's long-term TAM in PCIe/CXL interconnects if Korean fabs bypass US-based IP partners.", 'The 188% volume surge suggests institutional distribution — possibly hedge funds unwinding crowded AI infrastructure positions ahead of inflation data and Q2 earnings season, implying rational risk management rather than mispricing.']
Risk Factors
Upcoming CPI print causing broader market volatility | Unexpected weakness in next-gen CXL adoption timelines | Rapid deterioration in SPY/XLK technical structure triggering further sector rotation
Expected Recovery
14 days
Entry: $392.00
Current: $322.29
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-13
SNDK
Signal Narrative
N/A
Why We Bought
The drop is predicated on a non-existent security — SNDK was de-listed in 2016 and absorbed into Western Digital (WDC). All cited news sources conflate legacy branding with current reality, and no primary source (SEC filing, press release, earnings call) substantiates any event affecting 'SNDK'. While Devil's Advocate raises valid concerns about sector sentiment, a -11% move in a defunct ticker violates basic market microstructure hygiene and reflects data-layer failure — not rational price discovery.
What Market Missed (2nd Order)
Misallocation of attention toward obsolete symbols may delay capital reallocation to actual memory players (WD, MU, WDC), creating relative value dislocations; however, this does not justify -11% move in a non-existent security — it reveals systemic data feed/labeling failure, not fundamental risk.
Devil's Advocate
['1. Market may be pricing in broader NAND supply-demand deterioration due to Chinese capacity expansion, regardless of ticker accuracy; 2. Retail/algorithmic traders often trade legacy tickers reflexively during sector-wide selloffs, creating self-fulfilling liquidity cascades; 3. Even if SNDK is defunct, confusion could signal weakening investor confidence in the entire memory ecosystem — including WD, SK Hynix, Micron — making the selloff a rational proxy hedge.']
Risk Factors
Persistent data feed errors delaying correction | Regulatory scrutiny triggering short-selling halts on erroneous symbols | Contagion to actual memory stocks (WDC, MU) if confusion spreads
Expected Recovery
1–3 days (once data vendors correct ticker mapping and algos stop routing flow to invalid symbol)
Entry: $1654.03
Current: $1335.83
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-10
AXTI
Signal Narrative
N/A
Why We Bought
Devil's Advocate points are speculative and lack evidentiary support: no earnings date conflict, no TSMC capex revision reported, and options flow shows no abnormal put skew (Moomoo link is just a static chain display, not indicative of gamma exposure). Crucially, the narrative source is rumor — confidence ceiling is 55%, yet all available facts contradict it. The magnitude (-10.79%) vastly exceeds any plausible fundamental deterioration, especially given SPY’s +0.2% and AXTI’s historically low beta (0.82) to Nasdaq.
What Market Missed (2nd Order)
If the selloff is purely rumor-driven and liquidity dries up, short-term technical damage could trigger algorithmic stop-loss cascades — but this creates a self-correcting opportunity if fundamentals remain intact. AXTI’s core GaAs/InP substrate business serves RF, photonics, and power electronics — markets with multi-year visibility and low correlation to AI server capex cycles.
Devil's Advocate
['1. Market may be front-running an imminent earnings miss — AXTI’s next report is due in ~3 weeks (Q2 FY2026), and consensus EPS expectations have risen sharply amid AI-driven euphoria, increasing vulnerability to even modest guidance caution. 2. The -9.7% excess decline vs XLK (-1.1%) suggests embedded idiosyncratic risk — perhaps undisclosed customer concentration or inventory correction at key foundry customers (e.g., TSMC slowdown in advanced packaging capex). 3. Options chain (Moomoo reference) shows elevated put activity — sophisticated players may possess non-public supply-chain intel indicating near-term order deferrals.']
Risk Factors
Unscheduled earnings pre-announcement (low probability, <5%) | XLK sector-wide deterioration accelerating beyond -1.1% | Liquidity vacuum persists due to low volume (-7% vs 30-day avg)
Expected Recovery
8–12 trading days
Entry: $56.76
Current: $73.99
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-07
UCTT
Signal Narrative
N/A
Why We Bought
Market conflated routine capital structure optimization with fundamental weakness — ignoring UCTT’s strong cash position, raised guidance, and sector-normal ATM usage. Devil’s Advocate concerns about timing and dilution are valid but overweighed: the 8-K contains zero negative operational language, and peer precedent shows such offerings rarely precede earnings deterioration. The -8.2% excess move vs XLK far exceeds historical median reaction (-2.1% avg for ATM announcements in SEMI equipment group).
What Market Missed (2nd Order)
Short-term liquidity overreaction may create buying opportunity for long-term holders; if execution is disciplined (e.g., only drawing on ATM during pullbacks or for strategic M&A), it could enhance capital efficiency without harming ROIC — potentially supporting valuation re-rating in 3–6 months.
Devil's Advocate
['ATM programs often precede meaningful dilution; even if not immediate, $400M implies >10% potential share count increase at current price, pressuring EPS and signaling management expects sustained capital needs.', "The timing is suspicious: offering announced just after a strong Q2 beat — possibly reflecting management's view that the rally was unsustainable amid softening memory capex trends (confirmed by recent Lam/AMAT order revisions).", "Semiconductor equipment valuations are highly sensitive to forward cash flow visibility; any signal of 'funding flexibility' can trigger de-rating, especially when peer multiples are compressing (XLK down 0.4% on day, SPY -0.2%)."]
Risk Factors
Broader semiconductor capex slowdown accelerates beyond current expectations (e.g., DRAM foundry cuts deepen) | ATM execution triggers >12% dilution within 60 days without offsetting catalysts | SPY/XLK enters correction phase (>5% further decline), dragging quality names indiscriminately
Expected Recovery
14 days
Entry: $90.07
Current: $83.38
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-02
SLS
Signal Narrative
N/A
Why We Bought
Devil's Advocate points are valid but overstate risk: (1) No evidence of actual AML delay — only 'uncertainties' cited secondhand; (2) Extreme valuation reflects optionality, not fundamentals — and that optionality remains fully intact per public pipeline updates; (3) Volume decline is consistent with Q3 fatigue, not new negative catalyst. Crucially, the -6.6% *excess* drop vs XLV (-1.3%) confirms idiosyncratic overreaction — not macro or sector drag.
What Market Missed (2nd Order)
If AML timeline remains intact (no official delay confirmed), the overreaction creates asymmetric entry for catalyst-driven rebound ahead of GALA-3 top-line (expected H1 2027); preclinical differentiation in resistant PDAC may accelerate IND-enabling work and attract non-dilutive funding.
Devil's Advocate
["1. Preclinical pancreatic data does not offset clinical-stage AML risk: AML is SLS's lead program (Phase 3 GALA-3 for relapsed/refractory AML); any slippage there materially impacts near-term value inflection and partnership likelihood. 2. Valuation is extreme: 3-year 7x return implies >90% probability of Phase 3 success — a single negative update destroys optionality premium. 3. Volume decline (-28%) suggests institutional withdrawal, not retail panic; this is consistent with systematic de-risking in biotech after Q3 underperformance (SLS down 16.6% in Q3 vs XBI -8.2%)."]
Risk Factors
Unannounced AML protocol amendment or enrollment pause | Failure to initiate SLS009 IND by end-2026 | Broader biotech selloff intensifying (XBI < -5% over next 5 days)
Expected Recovery
14 days
Entry: $13.20
Current: $11.22
Stop Loss: -8%
Take Profit: +15%
AIP
Signal Narrative
N/A
Why We Bought
Devil's Advocate points are plausible but lack evidentiary support: no governance red flags in recent filings, liquidity metrics (avg 30d ADTV ~$45M) comfortably absorb the insider sales, and peer divergence confirms this wasn’t sector-driven. The magnitude (-20%) vastly exceeds any verifiable catalyst — consistent with historical mispricing in low-float, high-growth IP stocks during low-volume summer sessions. Recovery is probable once order flow normalizes.
What Market Missed (2nd Order)
Reduced analyst coverage visibility due to volatility stigma; possible delay in institutional index inclusion (e.g., Russell reconstitution eligibility depends on stable float and price continuity); temporary dislocation from fundamental valuation drivers (AIP trades at ~25x forward sales, below peer median of 32x, with >90% recurring license revenue).
Devil's Advocate
['1. The $3.18M director sale—though likely pre-arranged—may signal loss of confidence at the board level, especially if undisclosed governance concerns exist; 2. AIP is a micro-cap semiconductor IP play ($1.6B) with thin liquidity—-19.97% drop on +33% volume suggests a short squeeze reversal or algorithmic stop-loss cascade that exposed structural fragility; 3. XLK was down -2.7%, but semiconductor stocks like NVDA, AMD, LRCX all rose or fell <1%—AIP’s -17.3% excess vs XLK implies idiosyncratic risk the market priced in correctly, possibly related to unreported design-win delays or foundry partner issues.']
Risk Factors
Unannounced customer design-win cancellation | Unexpected Q2 guidance whisper downgrade | Broad semiconductor liquidity freeze (e.g., US export restriction escalation)
Expected Recovery
12–18 trading days
Entry: $34.38
Current: $30.16
Stop Loss: -8%
Take Profit: +15%
IREN
Signal Narrative
N/A
Why We Bought
While Devil's Advocate points highlight legitimate macro and sentiment risks, they do not justify a -13.6% single-day collapse absent any adverse fundamental catalyst. The drop vastly exceeds peer underperformance (-12.0% vs XLF), yet IREN alone has binding, funded contracts with tier-1 tech partners — a structural differentiator absent in CORZ/BTBT/MARA. Historical precedent shows AI infrastructure enablers recover swiftly when narrative resets from 'speculative miner' to 'de-risked capacity provider'.
What Market Missed (2nd Order)
Potential acceleration of analyst coverage upgrades if Q3 progress updates (e.g., Phase 1 deployment milestones with Microsoft) land ahead of expectations — mispricing creates asymmetric upside for early re-entry.
Devil's Advocate
['1. IREN is trading at extreme forward multiples (EV/Sales > 8x for unproven AI infrastructure revenue), making it vulnerable to any sentiment shift on delivery timelines — especially amid rising interest rates and SPY/XLF weakness.', '2. The 44% volume surge suggests institutional distribution, possibly triggered by hedge fund de-risking ahead of Q3 earnings season and AI capex scrutiny.', '3. Peer contagion is real: TeraWulf and Applied Digital down 30% in a month (Yahoo #7) implies sector-wide skepticism on capital discipline and power procurement scalability — IREN faces identical constraints given its 5-GW roadmap.']
Risk Factors
Failure to meet Q3 milestone disclosures (e.g., grid interconnection approval for first 1GW site) | Material delay in Microsoft/Nvidia payment terms triggering working capital stress | SPY decline >3% over next 5 trading days amplifying sector-wide deleveraging
Expected Recovery
14–21 days
Entry: $38.67
Current: $39.70
Stop Loss: -8%
Take Profit: +15%
Entered 2026-07-01
BRUN
Signal Narrative
N/A
Entry: $33.31
Current: $19.69
Stop Loss: -8%
Take Profit: +15%
📄 Latest Analysis Report
# Signal Performance Report — 2026-10-16
## Verdict Accuracy
### MISJUDGMENT (609 signals)
- ❌ **NBIS** (2026-07-01) drop:-14.9% → Day30:-19.4% [-] conf:78% Meta’s reported entry into AI cloud infr
- ✅ **WIT** (2026-07-01) drop:-14.9% → Day30:+3.4% [-] conf:78% JPMorgan slashed WIT's price target, sig
- ❌ **BRUN** (2026-07-01) drop:-14.0% → Day30:-41.5% [-] conf:72% 市场因不明负面事件或 liquidity-driven panic sold B
- ✅ **PVLA** (2026-07-01) drop:-10.3% → Day30:+3.1% [-] conf:78% 市场将未披露内容的8-K文件解读为负面监管/clinical setback信号
- ❌ **SLS** (2026-07-01) drop:-8.3% → Day30:-26.3% [-] conf:72% 市场将SLS近期大幅上涨（近翻倍）视为不可持续，叠加技术性获利回吐和估值担忧，认
- ❌ **LUMN** (2026-07-01) drop:-5.5% → Day30:-10.8% [-] conf:82% 市场将LUMN 5.53%下跌归因于 a $175M dilutive fina
- ❌ **SPCX** (2026-07-01) drop:-7.0% → Day30:-31.8% [-] conf:72% 市场将SpaceX近期AI-related hype (e.g., 'AI in
- ❌ **VRT** (2026-07-01) drop:-6.3% → Day30:-22.0% [-] conf:82% 市场在无明确负面催化剂下，对Vertiv的高估值和AI主题溢价产生突然性获利了结
- ❌ **CRWV** (2026-07-01) drop:-13.9% → Day30:-15.8% [-] conf:78% Meta’s entry into AI cloud services thre
- ❌ **IREN** (2026-07-01) drop:-5.3% → Day30:-14.8% [-] conf:78% IREN’s 5.27% drop is driven by market fe
- ❌ **RGC** (2026-07-02) drop:-20.6% → Day29:-6.3% [-] conf:78% 市场因不明负面事件或 liquidity-driven panic 抛售 RGC
- ❌ **AIP** (2026-07-02) drop:-21.1% → Day29:-12.2% [-] conf:78% 市场将AIP的-21%暴跌归因为未披露的重大负面事件（如并购失败、客户流失或技术
- ❌ **VICR** (2026-07-02) drop:-18.8% → Day29:-25.7% [-] conf:78% Vicor股价暴跌源于集中披露的多笔高管及机构 insider 卖出（含10b5
- ✅ **ORKA** (2026-07-02) drop:-11.4% → Day29:+16.6% [-] conf:78% Market is punishing ORKA for a large ins
- ❌ **AEIS** (2026-07-02) drop:-13.8% → Day29:-4.4% [-] conf:78% 市场因不明负面催化剂抛售AEIS，尽管同日获得 Wells Fargo 升级至O
- ❌ **WULF** (2026-07-02) drop:-10.9% → Day29:-15.3% [-] conf:78% WULF plunged on news of a secondary stoc
- ❌ **IREN** (2026-07-02) drop:-10.3% → Day29:-5.0% [-] conf:78% IREN is collapsing due to perceived comp
- ✅ **LUMN** (2026-07-02) drop:-10.6% → Day29:+1.3% [-] conf:72% 市场将LUMN解读为基本面持续恶化、转型失败且缺乏可信催化剂的‘dying te
- ✅ **LCID** (2026-07-02) drop:-8.4% → Day29:+21.2% [-] conf:82% Investors punished Lucid for CFO turnove
- ❌ **NBIS** (2026-07-02) drop:-7.8% → Day29:-10.4% [-] conf:78% Meta’s rumored plan to launch a competin
- ❌ **TSLA** (2026-07-02) drop:-8.0% → Day29:-20.5% [-] conf:78% Tesla beat delivery expectations but sha
- ❌ **ENS** (2026-07-02) drop:-6.7% → Day29:-8.9% [-] conf:82% 市场将ENS与加密项目ENS DAO的治理提案错误关联，引发对主业信用风险的误读
- ❌ **HTFL** (2026-07-02) drop:-8.9% → Day29:-9.1% [-] conf:78% 市场在无明确负面催化剂下恐慌性抛售，可能误读宏观情绪或错将板块强势视为个股压力源
- ❌ **APP** (2026-07-02) drop:-6.7% → Day29:-26.8% [-] conf:78% 市场因财报季临近+板块轮动+无明确负面催化剂而恐慌抛售，误将正常波动解读为基本面
- ❌ **SLBT** (2026-07-06) drop:-20.4% → Day30:-40.7% [-] conf:62% SLBT plunged 20.4% amid broad pre-market
- ❌ **ULS** (2026-07-06) drop:-7.8% → Day30:-12.3% [-] conf:72% 市场将ULS大跌归因为AI相关业务承压或行业情绪传染，但无具体负面事件支撑，仅伴
- ✅ **HAWK** (2026-07-06) drop:-5.0% → Day30:+17.9% [-] conf:72% 市场因不明负面事件或 liquidity-driven sell-off in
- ❌ **LBTYB** (2026-07-06) drop:-14.9% → Day30:+nan% [-] conf:72% Market is pricing in unannounced negativ
- ✅ **CBRS** (2026-07-06) drop:-6.3% → Day30:+13.1% [-] conf:74% 市场将Binance股票代币上市（中性/利好事件）与集体诉讼公告（负面信号）混同
- ❌ **VECO** (2026-07-06) drop:-5.3% → Day30:-3.2% [-] conf:74% VECO plunged 18% (pre-market) on Q1 2026
- ✅ **LFTO** (2026-07-06) drop:-5.2% → Day30:+9.2% [-] conf:72% 市场将LFTO与LUNR（Lunar Outpost）的Space Force合
- ❌ **RIVN** (2026-07-07) drop:-17.3% → Day30:-7.5% [-] conf:78% Rivian因宣布1.7亿美元增发（7500万股）引发严重稀释担忧，市场将其解读
- ❌ **UCTT** (2026-07-07) drop:-14.7% → Day30:-7.1% [-] conf:78% UCTT plunged amid broad semiconductor se
- ✅ **TWST** (2026-07-07) drop:-8.5% → Day30:+19.6% [-] conf:72% 市场将Evercore ISI从Outperform下调至In-Line解读为负
- ❌ **ALAB** (2026-07-07) drop:-11.9% → Day30:-11.0% [-] conf:78% Chairman Alba’s $60.5M insider sale sign
- ✅ **LCID** (2026-07-07) drop:-9.7% → Day30:+16.5% [-] conf:74% Lucid’s Q2 deliveries missed expectation
- ✅ **COMP** (2026-07-07) drop:-7.2% → Day30:+4.2% [-] conf:78% 市场因不明负面事件抛售COMP, 误将无关新闻（如AWK、Rivian、Chip
- ✅ **BFLY** (2026-07-07) drop:-7.2% → Day30:+9.8% [-] conf:74% 市场因信息真空与反向信号混淆而恐慌抛售：同一日出现‘23%盘前暴涨’报道与-7.
- ❌ **WULF** (2026-07-07) drop:-8.6% → Day30:-12.3% [-] conf:82% 市场误将TeraWulf的利好公告日（周一早盘大涨）与实际交易日（周一下跌）混淆
- ❌ **NBIS** (2026-07-07) drop:-6.8% → Day30:-3.2% [-] conf:74% Meta's entry into cloud compute capacity
- ❌ **IREN** (2026-07-07) drop:-7.8% → Day30:-4.9% [-] conf:72% IREN is collapsing because it 'missed' a
- ✅ **DJT** (2026-07-07) drop:-5.8% → Day30:+18.4% [-] conf:72% Market is punishing DJT amid renewed neg
- ❌ **ENS** (2026-07-07) drop:-8.1% → Day30:-3.1% [-] conf:72% 市场将ENS与同板块电子制造股（ETN, EMR, FELE）一同归类为'高估值
- ✅ **AEIS** (2026-07-07) drop:-7.3% → Day30:+13.1% [-] conf:72% AEIS sold off as part of broad semicondu
- ❌ **ALHC** (2026-07-08) drop:-14.1% → Day30:-30.3% [-] conf:74% 市场因 whistleblower lawsuit（举报人诉讼）恐慌性抛售，认为
- ✅ **BSP** (2026-07-08) drop:-8.4% → Day30:+28.6% [-] conf:78% 市场将BSP纳入纳斯达克综合指数与Franklin BSP相关CLO/债务实体的
- ✅ **NAVN** (2026-07-08) drop:-7.0% → Day30:+14.8% [-] conf:72% Market is pricing in unannounced negativ
- ❌ **BDRX** (2026-07-08) drop:-6.7% → Day30:-38.0% [-] conf:58% 市场因不明负面事件抛售BDRX, 暗示潜在管线失败、 regulatory se
- ✅ **SAIL** (2026-07-08) drop:-6.7% → Day30:+21.4% [-] conf:68% 市场将Rosenblatt中性评级（$16 PT）与 insider resal
- ❌ **ABCL** (2026-07-08) drop:-7.7% → Day30:-4.7% [-] conf:72% 市场因不明负面事件抛售ABCL，尽管当日有多个正面催化剂（Buy rating,
- ❌ **NTLA** (2026-07-09) drop:-8.1% → Day29:-22.8% [-] conf:74% Market is pricing in broad biotech secto
- ✅ **AXTI** (2026-07-10) drop:-9.5% → Day28:+55.0% [-] conf:78% 市场将AI聚焦的Indium Phosphide（InP）合作与Russell指
- ❌ **MRNA** (2026-07-10) drop:-10.4% → Day28:-14.6% [-] conf:78% Biotech sector-wide selloff driven by ma
- ✅ **TARS** (2026-07-10) drop:-9.6% → Day28:+10.8% [-] conf:78% Market interpreted the iRenix acquisitio
- ❌ **DOCN** (2026-07-10) drop:-7.0% → Day28:-5.3% [-] conf:78% Market is punishing DOCN despite recent
- ❌ **ATEX** (2026-07-10) drop:-5.0% → Day28:-3.0% [-] conf:72% 市场因不明负面事件或流动性扰动抛售ATEX，但无实质性利空信息支撑
- ❌ **WULF** (2026-07-10) drop:-5.5% → Day28:-23.0% [-] conf:74% Market is punishing WULF for crypto weak
- ❌ **MARA** (2026-07-10) drop:-5.5% → Day28:-20.9% [-] conf:76% MARA plunged -5.45% despite positive new
- ❌ **IONS** (2026-07-10) drop:-9.4% → Day28:-3.3% [-] conf:78% Ionis/AZ Phase 3 ATTR-CM trial missed pr
- ✅ **SAIL** (2026-07-10) drop:-7.7% → Day28:+33.8% [-] conf:72% 高管集中减持引发对公司基本面或 governance 的担忧，暗示内部人看空未来
- ✅ **MRCY** (2026-07-10) drop:-5.5% → Day28:+1.0% [-] conf:72% Market downgrades MRCY due to 'investmen
- ✅ **RGC** (2026-07-13) drop:-13.4% → Day30:+0.2% [-] conf:62% 市场因不明负面事件或流动性冲击对RGC进行抛售，叠加小盘生物科技股流动性脆弱性放
- ❌ **APP** (2026-07-13) drop:-12.2% → Day30:-31.4% [-] conf:72% 市场因不明负面事件抛售APP，叠加高成交量与显著超额跌幅，暗示突发性信心崩塌，但
- ✅ **AXTI** (2026-07-13) drop:-14.1% → Day30:+59.1% [-] conf:68% 市场因缺乏明确负面催化剂而恐慌性抛售，叠加板块拖累和流动性压力，形成'无叙事下跌
- ❌ **BDRX** (2026-07-13) drop:-10.8% → Day30:-32.4% [-] conf:58% 市场因不明负面事件抛售BDRX，隐含叙事为‘管线受挫或监管失败’，但无公开信息支
- ❌ **SNDK** (2026-07-13) drop:-13.5% → Day30:-19.1% [-] conf:72% Sandisk plunged alongside memory chip pe
- ✅ **MRCY** (2026-07-13) drop:-9.6% → Day30:+14.8% [-] conf:62% 市场因JPMorgan‘flags near-term strain’及板块普跌
- ❌ **WULF** (2026-07-13) drop:-5.7% → Day30:-16.8% [-] conf:72% 市场因SeekingAlpha发布的'Sell'评级及TechStock²对$3
- ✅ **IREN** (2026-07-13) drop:-5.2% → Day30:+12.2% [-] conf:74% 市场将CEO获授7.49亿美元股票奖励解读为严重公司治理风险与潜在稀释信号，叠加
- ✅ **AUR** (2026-07-13) drop:-5.8% → Day30:+15.1% [-] conf:62% 市场因缺乏明确负面催化剂而对AUR进行恐慌性抛售，叠加流动性萎缩（成交量-40%
- ✅ **SPCX** (2026-07-13) drop:-5.2% → Day30:+8.3% [-] conf:62% SpaceX is overvalued, lacks near-term pr
- ❌ **ALAB** (2026-07-13) drop:-12.3% → Day30:-9.6% [-] conf:74% Astera Labs sold off with broader semico
- ✅ **EWTX** (2026-07-13) drop:-9.1% → Day30:+5.7% [-] conf:78% 市场将Servier收购Edgewise肌肉萎缩症业务解读为公司核心价值坍塌、管
- ❌ **BYND** (2026-07-13) drop:-5.3% → Day30:-34.5% [-] conf:72% 市场在无明确负面催化剂下，对BYND进行恐慌性抛售，可能受流动性枯竭、做空挤压平
- ✅ **SKM** (2026-07-13) drop:-5.2% → Day30:+11.3% [-] conf:72% SK Telecom sold off alongside broader te
- ✅ **IBM** (2026-07-14) drop:-24.3% → Day30:+8.1% [-] conf:74% IBM plunged 24.3% after preliminary Q2 r
- ✅ **ERIC** (2026-07-14) drop:-13.4% → Day30:+1.0% [-] conf:74% ERIC missed revenue by $418M (7.2% below
- ✅ **LCID** (2026-07-14) drop:-13.4% → Day30:+33.9% [-] conf:52% Market is pricing in imminent bankruptcy
- ✅ **DNLI** (2026-07-14) drop:-15.2% → Day30:+11.3% [-] conf:72% Denali's Parkinson's drug (DNL151/BIIB09
- ❌ **WULF** (2026-07-14) drop:-8.6% → Day30:-15.0% [-] conf:78% 市场因WULF宣布3.5B美元债务融资用于Kentucky数据中心建设，叠加9%
- ✅ **NBIS** (2026-07-14) drop:-6.1% → Day30:+27.8% [-] conf:72% Market fears Meta's entry into cloud cap
- ✅ **BIIB** (2026-07-14) drop:-7.9% → Day30:+9.1% [-] conf:78% Diranersen Phase 2 CELIA trial missed pr
- ✅ **LBTYB** (2026-07-14) drop:-5.2% → Day30:+0.5% [-] conf:72% 市场因不明负面催化剂抛售LBTYB, 暗示潜在结构性恶化或 hidden ris
- ✅ **CELC** (2026-07-15) drop:-17.4% → Day30:+0.0% [-] conf:78% 市场将FDA批准REVTORPYK解读为利好，但同步消化了‘延迟 launch’
- ❌ **NAMSW** (2026-07-15) drop:-15.8% → Day30:+nan% [-] conf:72% 市场将Biogen阿尔茨海默病药物diranersen的负面数据错误关联至NAM
- ✅ **AAOI** (2026-07-15) drop:-12.8% → Day30:+37.1% [-] conf:78% AAOI sold off sharply as part of a broad
- ❌ **LEGN** (2026-07-15) drop:-9.5% → Day30:-12.7% [-] conf:72% 市场因CARVYKTI销售数据不及预期或隐含增长放缓担忧而抛售，尽管分析师维持$
- ✅ **QNT** (2026-07-15) drop:-10.8% → Day30:+9.0% [-] conf:78% 市场将Quantinuum与Rolls-Royce的量子计算合作解读为‘comm
- ✅ **DELL** (2026-07-15) drop:-9.8% → Day30:+18.6% [-] conf:78% AI hardware stocks are correcting sharpl
- ❌ **MBLY** (2026-07-15) drop:-6.5% → Day30:-5.1% [-] conf:62% 市场担忧Mobileye基本面恶化或行业竞争加剧，但无具体事件支撑，下跌缺乏明确
- ✅ **MANE** (2026-07-16) drop:-13.6% → Day29:+5.0% [-] conf:78% 市场在利好密集发布日反向大跌，叙事缺失——无明确bearish catalyst
- ❌ **ERAS** (2026-07-16) drop:-11.3% → Day29:-3.2% [-] conf:78% 市场将大规模股权融资（+36M shares, ~$650M gross pro
- ✅ **MXL** (2026-07-16) drop:-15.6% → Day29:+11.9% [-] conf:72% MXL plunged alongside broad semiconducto
- ✅ **AXTI** (2026-07-16) drop:-15.2% → Day29:+79.7% [-] conf:74% AXTI abruptly abandoned its Tongmei Shan
- ✅ **NBIS** (2026-07-16) drop:-12.5% → Day29:+56.3% [-] conf:72% NBIS大跌源于市场对Meta新AI cloud服务带来的竞争压力的恐慌性解读，
- ✅ **PL** (2026-07-16) drop:-11.1% → Day29:+10.8% [-] conf:72% Planet Labs is collapsing due to structu
- ❌ **ATEX** (2026-07-16) drop:-10.9% → Day29:-5.8% [-] conf:72% 市场将Anterix归类为'估值派对终结'的高倍数通信股，担忧其缺乏近期盈利催化
- ✅ **BYND** (2026-07-16) drop:-5.4% → Day29:+2130.3% [-] conf:58% 市场将BYND大跌归因于‘弱展望’和CFO税务扣留事件，暗示公司基本面恶化或 g
- ❌ **HOOD** (2026-07-16) drop:-7.8% → Day29:-10.0% [-] conf:78% Market interpreted ARK's $3.9M Robinhood
- ✅ **IREN** (2026-07-16) drop:-7.6% → Day29:+25.7% [-] conf:72% IREN is collapsing as part of the broade
- ❌ **RIVN** (2026-07-16) drop:-5.9% → Day29:-7.5% [-] conf:78% Market is pricing in deteriorating funda
- ✅ **MRCY** (2026-07-16) drop:-6.1% → Day29:+13.8% [-] conf:72% Market is pricing in broad industrials/d
- ✅ **ALB** (2026-07-16) drop:-5.0% → Day29:+14.5% [-] conf:72% 市场将ALB近期持续疲软（4周-25.1%）与锂行业整体叙事恶化挂钩，隐含担忧其
- ❌ **MBLY** (2026-07-16) drop:-5.0% → Day29:-0.1% [-] conf:68% Market anticipates significant EPS decli
- ✅ **ISRG** (2026-07-17) drop:-13.2% → Day28:+13.9% [-] conf:78% ISRG tanked despite beating Q2 EPS and r
- ❌ **CDNS** (2026-07-17) drop:-9.6% → Day28:-1.0% [-] conf:62% Kimi K3 AI model reportedly designed a c
- ✅ **SNPS** (2026-07-17) drop:-9.3% → Day28:+11.5% [-] conf:72% Kimi K3 AI model demonstrated chip desig
- ✅ **HCM** (2026-07-17) drop:-6.5% → Day28:+12.3% [-] conf:72% 市场因不明负面消息或流动性扰动抛售HCM，叠加大盘疲软放大跌幅
- ❌ **MARA** (2026-07-17) drop:-6.5% → Day28:-13.8% [-] conf:74% MARA is collapsing due to structural det
- ✅ **SPCX** (2026-07-17) drop:-5.4% → Day28:+12.4% [-] conf:78% SpaceX stock collapsed due to Starship F
- ❌ **BILI** (2026-07-17) drop:-5.2% → Day28:-3.6% [-] conf:78% 市场因混淆BILI（Bilibili Inc., NASDAQ）与同名但无关的瑞
- ✅ **PENG** (2026-07-17) drop:-8.4% → Day28:+2.3% [-] conf:72% 市场将PENG的-8.43%下跌归因为潜在基本面恶化或行业风险，但无具体事件支撑
- ❌ **HOOD** (2026-07-17) drop:-5.7% → Day28:-4.1% [-] conf:72% Robinhood sold off sharply due to a broa
- ✅ **RGTIW** (2026-07-20) drop:-28.0% → Day30:+31.3% [-] conf:68% Quantum computing sector-wide selloff ca
- ✅ **PVLA** (2026-07-20) drop:-19.6% → Day30:+17.8% [-] conf:62% 市场因不明负面事件或传言对PVLA进行恐慌性抛售，叠加高成交量放大情绪，但无实质
- ✅ **PENG** (2026-07-20) drop:-11.8% → Day30:+1.4% [-] conf:78% 市场将750M可转债发行解读为财务压力信号，暗示公司现金流紧张或估值过高，需稀释
- ❌ **IMOS** (2026-07-20) drop:-8.6% → Day30:-16.6% [-] conf:78% 市场将IMOS的-8.55%大跌错误归因为负面基本面事件, 实际主因是股息除权日
- ✅ **TRVI** (2026-07-20) drop:-9.9% → Day30:+8.7% [-] conf:72% 市场因不明负面催化剂抛售TRVI，尽管多家顶级分析师同步上调目标价并重申买入评级
- ✅ **LBTYB** (2026-07-20) drop:-6.2% → Day30:+18.2% [-] conf:72% 市场因不明负面信号抛售LBTYB, 暗示潜在未披露风险或隐性恶化（如 lever
- ❌ **SEDG** (2026-07-20) drop:-9.1% → Day30:-33.2% [-] conf:62% TD Cowen下调目标价至$75（-12% from prior $85）并维
- ✅ **RGTIW** (2026-07-21) drop:-20.3% → Day30:+7.4% [-] conf:62% Quantum computing sector-wide selloff dr
- ✅ **TENB** (2026-07-21) drop:-10.0% → Day30:+1.0% [-] conf:72% Truist downgraded TENB from Buy to Hold
- ✅ **DHR** (2026-07-21) drop:-11.2% → Day30:+22.1% [-] conf:78% 市场因Danaher上调全年EPS指引但下调核心收入指引（尤其生物工艺交付延迟）
- ✅ **FIG** (2026-07-21) drop:-8.8% → Day30:+25.2% [-] conf:62% 市场将FIG大跌归因为AI基础设施泡沫破裂与企业AI支出放缓，叠加‘AI uni
- ✅ **MSCI** (2026-07-21) drop:-10.1% → Day30:+1.2% [-] conf:78% 市场将强劲Q2财报误读为增长见顶信号，因股价在beat后暴跌，暗示投资者担忧AI
- ❌ **OMCL** (2026-07-21) drop:-7.0% → Day30:-14.8% [-] conf:72% Market is pricing in imminent negative c
- ✅ **FA** (2026-07-21) drop:-5.3% → Day30:+0.1% [-] conf:68% 市场在无明确负面催化剂下抛售FA，可能因流动性错觉或微观结构扰动（如算法平仓、期
- ❌ **FLUT** (2026-07-21) drop:-5.2% → Day30:-0.5% [-] conf:62% Wells Fargo下调Flutter目标价23%（$168→$137）并维持
- ✅ **RGTIW** (2026-07-22) drop:-20.3% → Day30:+30.7% [-] conf:62% Market is pricing in existential risk to
- ✅ **PEGA** (2026-07-22) drop:-17.4% → Day30:+30.9% [-] conf:72% PEGA missed Q2 EPS and revenue estimates
- ✅ **PATH** (2026-07-22) drop:-12.2% → Day30:+53.2% [-] conf:68% UiPath plunged -12.2% amid broad softwar
- ✅ **RDY** (2026-07-22) drop:-9.0% → Day30:+6.5% [-] conf:72% RDY missed Q4 FY2026 EPS and reported we
- ❌ **RDDT** (2026-07-22) drop:-8.8% → Day30:-10.0% [-] conf:72% Reddit may cut off Google’s AI access to
- ✅ **FA** (2026-07-22) drop:-6.5% → Day30:+5.1% [-] conf:78% 市场因不明负面催化剂抛售FA，可能误读无关SEC filings或混淆同名实体。
- ❌ **DJT** (2026-07-22) drop:-7.1% → Day30:-0.8% [-] conf:72% Truth API is ethically toxic and commerc
- ❌ **LCID** (2026-07-22) drop:-6.7% → Day30:-18.8% [-] conf:72% 市场将即将到期的集体诉讼原告截止日（7月28日）与实质性法律风险挂钩，叠加‘召回
- ✅ **SPCX** (2026-07-22) drop:-5.6% → Day30:+16.6% [-] conf:68% Market fears SpaceX is overvalued and fa
- ✅ **COIN** (2026-07-22) drop:-5.1% → Day30:+10.7% [-] conf:68% COIN is weakening due to leadership inst
- ✅ **NAVN** (2026-07-22) drop:-11.6% → Day30:+23.5% [-] conf:68% 市场因不明负面事件抛售Navan，但无实质性催化剂披露；叙事缺失，仅表现为技术性
- ✅ **NTES** (2026-07-22) drop:-6.4% → Day30:+5.9% [-] conf:72% NetEase dragged down by broad-based Chin
- ❌ **STM** (2026-07-23) drop:-18.6% → Day29:-5.3% [-] conf:78% STM plunged 18.6% on weak Q3 guidance de
- ✅ **MOH** (2026-07-23) drop:-10.5% → Day29:+1.1% [-] conf:74% Molina beat EPS but cut full-year revenu
- ✅ **MBLY** (2026-07-23) drop:-14.4% → Day29:+20.7% [-] conf:78% CEO resignation of founding visionary Am
- ✅ **PI** (2026-07-23) drop:-8.2% → Day29:+30.7% [-] conf:72% 市场因不明负面催化剂抛售Impinj，叠加大盘与板块普跌，形成恐慌性超调；叙事缺
- ✅ **COAG** (2026-07-23) drop:-5.6% → Day29:+5.6% [-] conf:68% 市场因缺乏明确负面催化剂而对COAG进行恐慌性抛售，可能混淆其为财报或监管事件股
- ✅ **TMUS** (2026-07-23) drop:-8.9% → Day29:+4.9% [-] conf:78% 市场因T-Mobile拒绝扩大Starlink合作+营收小幅不及预期而解读为增长
- ✅ **BYND** (2026-07-23) drop:-6.3% → Day29:+2548.2% [-] conf:62% 市场将BYND的大幅下跌归因于 impending Q2 earnings an
- ✅ **GOOGL** (2026-07-23) drop:-7.0% → Day29:+8.6% [-] conf:72% Alphabet beat earnings but plunged on fe
- ❌ **MXL** (2026-07-24) drop:-24.4% → Day28:-3.5% [-] conf:78% 尽管MXL公布强劲Q2财报（营收$168.8M，beat预期）并上调Q3 gui
- ✅ **NBIS** (2026-07-24) drop:-12.9% → Day28:+13.7% [-] conf:72% Nebius is being punished for relative un
- ✅ **HIMS** (2026-07-24) drop:-12.1% → Day28:+17.5% [-] conf:78% 市场将CAO离职与FDA肽类利好消息错误关联，解读为公司治理恶化信号，忽视事件时
- ✅ **AXTI** (2026-07-24) drop:-12.4% → Day28:+51.3% [-] conf:78% Market is pricing in undisclosed negativ
- ❌ **SMMT** (2026-07-24) drop:-9.1% → Day28:-3.6% [-] conf:72% Market interpreted in-line Q2 loss ($0.2
- ✅ **PL** (2026-07-24) drop:-8.2% → Day28:+8.8% [-] conf:72% No clear catalyst — market sold off PL o
- ✅ **IREN** (2026-07-24) drop:-7.7% → Day28:+10.5% [-] conf:68% Market is pricing in skepticism around I
- ✅ **LBTYA** (2026-07-24) drop:-7.1% → Day28:+11.1% [-] conf:74% Market punished LBTYA for Q2 2026 EPS an
- ❌ **WULF** (2026-07-24) drop:-7.4% → Day28:-16.9% [-] conf:62% 市场因CEO近期股票减持传闻而恐慌性抛售，叠加对算力基建股短期流动性担忧。
- ❌ **NVCR** (2026-07-24) drop:-11.7% → Day28:-3.3% [-] conf:78% 市场将Q2强劲财报（beat+guidance raise）误读为‘买预期卖事实
- ✅ **CRWV** (2026-07-24) drop:-11.4% → Day28:+22.9% [-] conf:72% AI infrastructure stocks are undergoing
- ✅ **HAWK** (2026-07-24) drop:-5.5% → Day28:+10.6% [-] conf:78% 市场将HAWK与无关的'Black Hawk'命名混淆（如BKHA、WSTM f
- ✅ **LEGN** (2026-07-27) drop:-13.7% → Day30:+8.0% [-] conf:72% CEO Huang's abrupt resignation—coupled w
- ✅ **SIMO** (2026-07-27) drop:-10.2% → Day30:+7.5% [-] conf:68% Market is pricing in a material negative
- ✅ **SHAZ** (2026-07-27) drop:-10.1% → Day30:+1.6% [-] conf:78% 市场因SEC 8-K文件突发披露而恐慌性抛售，隐含监管风险或重大不利事件。
- ❌ **ACHC** (2026-07-27) drop:-6.0% → Day30:-5.7% [-] conf:62% 市场担忧Acadia即将发布的Q2财报不及预期，或隐含对 behavioral
- ✅ **SNDK** (2026-07-27) drop:-11.0% → Day30:+17.5% [-] conf:87% China's state-backed CXMT IPO and domest
- ✅ **AMKR** (2026-07-28) drop:-23.5% → Day30:+10.6% [-] conf:76% Amkor beat Q2 EPS and revenue but cut ne
- ✅ **SHAZ** (2026-07-28) drop:-19.7% → Day30:+25.4% [-] conf:62% Market is pricing in imminent negative c
- ✅ **SKM** (2026-07-28) drop:-12.3% → Day30:+27.3% [-] conf:72% SK Telecom plunged -12.3% amid broad AI-
- ✅ **NBIS** (2026-07-28) drop:-10.0% → Day30:+28.1% [-] conf:72% Market is repricing NBIS amid confusion
- ❌ **NAMS** (2026-07-28) drop:-6.9% → Day30:-4.0% [-] conf:72% 市场将NAMS归类为‘AI chip-adjacent biotech’并因半导
- ✅ **PRAX** (2026-07-28) drop:-6.7% → Day30:+25.8% [-] conf:72% 市场将PRAX与NASA的'PRAXIS'任务混淆，误读为公司卷入高-risk
- ✅ **IREN** (2026-07-28) drop:-5.7% → Day30:+18.5% [-] conf:72% IREN’s $2B private offering signals dist
- ❌ **WULF** (2026-07-28) drop:-5.3% → Day30:-3.2% [-] conf:72% WULF’s stock is collapsing because New Y
- ❌ **VRT** (2026-07-28) drop:-6.2% → Day30:-0.4% [-] conf:72% Vertiv is pricing in imminent earnings d
- ✅ **SLS** (2026-07-28) drop:-6.9% → Day30:+52.2% [-] conf:78% Market interprets China arbitration loss
- ✅ **AEIS** (2026-07-28) drop:-6.3% → Day30:+4.1% [-] conf:72% AEIS is collapsing on semiconductor equi
- ✅ **PSN** (2026-07-29) drop:-35.3% → Day30:+22.5% [-] conf:78% Parsons missed revenue expectations and
- ✅ **ACHC** (2026-07-29) drop:-15.8% → Day30:+3.7% [-] conf:74% Market punished ACHC for 'soft guidance'
- ✅ **VRT** (2026-07-29) drop:-16.6% → Day30:+14.6% [-] conf:74% Vertiv stock collapsed on Q2 revenue mis
- ✅ **HIMS** (2026-07-29) drop:-13.0% → Day30:+12.0% [-] conf:72% FTC lawsuit alleging systemic privacy vi
- ✅ **APLD** (2026-07-29) drop:-10.5% → Day30:+5.9% [-] conf:78% Despite a massive Q4 beat and $20B backl
- ✅ **NBIS** (2026-07-29) drop:-9.1% → Day30:+35.2% [-] conf:68% AI infrastructure stocks are repricing d
- ✅ **IREN** (2026-07-29) drop:-10.3% → Day30:+16.3% [-] conf:68% IREN’s -10.29% drop reflects market pani
- ❌ **WULF** (2026-07-29) drop:-9.4% → Day30:-1.0% [-] conf:72% WULF is collapsing due to regulatory hea
- ✅ **PPG** (2026-07-29) drop:-6.3% → Day30:+2.3% [-] conf:74% PPG missed Q2 EPS by $0.03 ($2.23 vs $2.
- ❌ **MRCY** (2026-07-29) drop:-7.1% → Day30:-4.2% [-] conf:72% MRCY sold off sharply amid broad-based a
- ✅ **AXTI** (2026-07-29) drop:-13.5% → Day30:+60.5% [-] conf:74% AXT’s -13.5% crash reflects panic over B
- ✅ **RUM** (2026-07-29) drop:-6.1% → Day30:+60.3% [-] conf:58% 市场将RUM与AI compute pivot hype and broader
- ✅ **ALNY** (2026-07-30) drop:-30.0% → Day29:+17.6% [-] conf:78% ALNY plunged on Q2 revenue miss (-2.09%)
- ✅ **FICO** (2026-07-30) drop:-16.5% → Day29:+0.8% [-] conf:78% Despite beating Q3 EPS and raising full-
- ✅ **WAY** (2026-07-30) drop:-16.2% → Day29:+27.6% [-] conf:78% Despite beating Q2 EPS and revenue estim
- ✅ **CHKP** (2026-07-30) drop:-9.0% → Day29:+9.1% [-] conf:78% CHKP beat EPS but missed revenue and cut
- ✅ **FA** (2026-07-30) drop:-7.6% → Day29:+5.5% [-] conf:62% Market is pricing in undisclosed negativ
- ✅ **NIQ** (2026-07-30) drop:-5.3% → Day29:+70.3% [-] conf:72% 市场因缺乏明确负面催化剂而恐慌性抛售，可能误读中性/积极行业数据为需求疲软信号。
- ❌ **FLUT** (2026-07-30) drop:-5.4% → Day29:-0.9% [-] conf:72% Market is pricing in near-term earnings
- ✅ **FDS** (2026-07-30) drop:-5.5% → Day29:+15.8% [-] conf:72% 市场未给出明确叙事——FDS无相关财报、监管事件、并购或 sector-spec
- ✅ **META** (2026-07-30) drop:-8.8% → Day29:+8.1% [-] conf:72% Meta's massive AI spending is failing to
- ✅ **GWRE** (2026-07-30) drop:-8.4% → Day29:+34.0% [-] conf:72% 市场将Guidewire与Palantir关联性误读为竞争恶化或客户流失信号，叠
- ✅ **RBLX** (2026-07-31) drop:-27.6% → Day28:+8.5% [-] conf:74% Roblox stock collapsed on Q2 revenue mis
- ✅ **RDDT** (2026-07-31) drop:-20.5% → Day28:+8.6% [-] conf:72% Reddit beat Q2 earnings but stock collap
- ❌ **VCYT** (2026-07-31) drop:-21.9% → Day28:-6.5% [-] conf:78% VCYT beat Q2 EPS and revenue but cut ful
- ❌ **BTSGU** (2026-07-31) drop:-18.1% → Day28:+nan% [-] conf:78% 尽管Q2 EPS beat预期，市场因下调全年guidance、毛利率承压及客户
- ✅ **GDDY** (2026-07-31) drop:-15.3% → Day28:+15.9% [-] conf:74% GoDaddy beat Q2 EPS and revenue but cut
- ❌ **LCID** (2026-07-31) drop:-9.4% → Day28:-32.3% [-] conf:72% 市场将Prince Alwaleed的持股披露解读为潜在抛压或治理风险信号，叠加
- ✅ **RIVN** (2026-07-31) drop:-7.9% → Day28:+2.4% [-] conf:78% 市场在Q2财报后‘beat and dump’——尽管Rivian公布超预期业绩
- ✅ **AAPL** (2026-07-31) drop:-8.3% → Day28:+4.6% [-] conf:74% Apple's Q3 FY2026 earnings were 'in-line
- ✅ **CTVA** (2026-07-31) drop:-9.9% → Day28:+4.0% [-] conf:76% Despite beating EPS estimates, CTVA's -1
- ❌ **ALHC** (2026-07-31) drop:-20.2% → Day28:-7.0% [-] conf:76% Alignment Healthcare beat Q2 EPS and rev
- ✅ **SRAD** (2026-08-03) drop:-14.5% → Day30:+4.1% [-] conf:72% SRAD plunged 14.5% on Q2 earnings miss a
- ✅ **TGTX** (2026-08-03) drop:-11.2% → Day30:+24.1% [-] conf:78% TGTX stock plunged on Q2 EPS miss despit
- ❌ **ALMS** (2026-08-03) drop:-9.2% → Day30:-60.1% [-] conf:62% 市场因不明负面事件或 liquidity-driven panic 抛售 ALM
- ✅ **FICO** (2026-08-03) drop:-6.7% → Day30:+4.5% [-] conf:72% 市场因多名机构减持（含RBC、Amundi）及一则模糊的‘insider sel
- ✅ **CF** (2026-08-03) drop:-5.6% → Day30:+18.5% [-] conf:72% CF stock plunged -5.64% amid no clear ea
- ✅ **KRYS** (2026-08-03) drop:-8.4% → Day30:+18.0% [-] conf:78% KRYS stock plunged despite EPS beat beca
- ❌ **ICHR** (2026-08-04) drop:-11.7% → Day30:-25.7% [-] conf:78% ICHR plunged on Q2 revenue miss despite
- ❌ **ULS** (2026-08-04) drop:-14.5% → Day30:-4.0% [-] conf:78% 市场将强劲Q2财报（EPS+5.4%, revenue+0.5% beat）误读
- ✅ **VERX** (2026-08-04) drop:-9.4% → Day30:+14.4% [-] conf:72% Despite beating Q2 EPS and revenue, VERX
- ✅ **BHC** (2026-08-04) drop:-8.9% → Day30:+5.2% [-] conf:72% 市场因不明负面事件抛售BHC，叠加短期超买回调预期（前5日涨56%），形成恐慌性
- ✅ **VERA** (2026-08-04) drop:-7.2% → Day30:+16.6% [-] conf:72% 市场将Vera Therapeutics与无关的'Verafin'（被D-Wav
- ✅ **ALHC** (2026-08-04) drop:-7.1% → Day30:+0.1% [-] conf:72% Market is pricing in material legal and
- ❌ **SEDG** (2026-08-05) drop:-28.7% → Day30:-2.2% [-] conf:78% SolarEdge beat Q2 EPS but cut Q3 revenue
- ✅ **TDC** (2026-08-05) drop:-22.8% → Day30:+5.9% [-] conf:78% Teradata missed Q3 EPS and revenue guida
- ✅ **PODD** (2026-08-05) drop:-19.1% → Day30:+9.0% [-] conf:78% PODD crashed despite beating Q2 EPS and
- ✅ **SPCX** (2026-08-05) drop:-12.9% → Day30:+36.4% [-] conf:78% SpaceX delivered a massive revenue beat
- ✅ **LUMN** (2026-08-05) drop:-10.7% → Day30:+14.4% [-] conf:78% LUMN plunged on 'disappointing revenue d
- ❌ **PINS** (2026-08-05) drop:-8.5% → Day30:-12.7% [-] conf:78% Pinterest beat Q2 EPS and revenue but is
- ✅ **BLLN** (2026-08-06) drop:-38.8% → Day29:+9.0% [-] conf:72% BLLN plunged 38.8% on Q2 EPS miss ($0.15
- ✅ **HUBS** (2026-08-06) drop:-22.0% → Day29:+27.3% [-] conf:74% HubSpot beat EPS but cut full-year guida
- ❌ **APP** (2026-08-06) drop:-19.8% → Day29:-4.4% [-] conf:72% AppLovin股价暴跌源于Q3财报营收不及预期（'revenue miss'）
- ❌ **DDOG** (2026-08-06) drop:-19.1% → Day29:-7.1% [-] conf:78% Datadog delivered a strong beat-and-rais
- ✅ **GRAL** (2026-08-06) drop:-16.7% → Day29:+29.7% [-] conf:78% Despite beating revenue estimates ($44.7
- ✅ **BYND** (2026-08-06) drop:-14.7% → Day29:+2079.8% [-] conf:74% Market punished BYND for a modest EPS mi
- ✅ **NBIS** (2026-08-06) drop:-11.9% → Day29:+15.6% [-] conf:72% Market is punishing NBIS on profit-takin
- ✅ **MARA** (2026-08-06) drop:-5.2% → Day29:+5.7% [-] conf:74% Market interprets insider selling, price
- ✅ **BBY** (2026-08-06) drop:-5.3% → Day29:+13.1% [-] conf:72% Jefferies downgraded BBY to Hold citing
- ❌ **LASR** (2026-08-07) drop:-23.9% → Day28:-30.1% [-] conf:78% LASR plunged on Q3 guidance miss ($63–73
- ✅ **TTD** (2026-08-07) drop:-21.9% → Day28:+3.8% [-] conf:74% Investors are increasingly bearish on th
- ✅ **ARW** (2026-08-07) drop:-10.0% → Day28:+7.5% [-] conf:82% Despite strong Q2 beat and raised guidan
- ✅ **TDS** (2026-08-07) drop:-9.4% → Day28:+16.4% [-] conf:78% TDS stock plunged -9.44% despite a massi
- ✅ **ELAN** (2026-08-07) drop:-7.8% → Day28:+9.1% [-] conf:78% 市场将FDA紧急授权新药（screwworm drug）误读为短期成本压力或监管
- ❌ **XRAY** (2026-08-07) drop:-6.6% → Day28:-7.8% [-] conf:78% 尽管Q2 EPS大幅超预期（+50.1%）且营收小幅超预期（+1.6%），但市场
- ❌ **DPC** (2026-08-07) drop:-7.7% → Day28:-14.7% [-] conf:72% 市场因不明负面事件抛售DPC，但无实质性信息支撑，叙事缺失——仅存在泛泛的‘st
- ✅ **SION** (2026-08-10) drop:-91.3% → Day30:+66.6% [-] conf:78% SION-719 failure in CF Phase 2/3 (Precis
- ❌ **AXTI** (2026-08-10) drop:-15.8% → Day30:-7.5% [-] conf:72% AXTI plunged 15.85% amid unexplained pri
- ❌ **COHR** (2026-08-10) drop:-12.3% → Day30:-8.3% [-] conf:74% AI optics stocks (COHR, LUMT) are sellin
- ✅ **SLS** (2026-08-10) drop:-8.3% → Day30:+27.0% [-] conf:72% SLS plunged 8.3% amid unconfirmed negati
- ❌ **DJT** (2026-08-10) drop:-9.0% → Day30:-6.1% [-] conf:72% Market interprets Crypto.com venture ter
- ❌ **LCID** (2026-08-10) drop:-7.0% → Day30:-35.1% [-] conf:72% Lucid missed Q2 expectations and signale
- ✅ **BRVE** (2026-08-10) drop:-8.2% → Day30:+5.3% [-] conf:78% 市场因不明负面事件抛售BRVE，疑与8-K公告内容相关，但公开新闻未披露实质性不
- ❌ **LIF** (2026-08-11) drop:-26.2% → Day30:-12.2% [-] conf:74% Market interpreted LIF's Q2 earnings cal
- ❌ **NYAX** (2026-08-11) drop:-13.1% → Day30:-12.1% [-] conf:78% Market punished NYAX harshly for a large
- ❌ **FA** (2026-08-11) drop:-10.0% → Day30:-3.7% [-] conf:78% 市场将Silver Lake大规模二级出售（12.5M股+潜在87.45M股）解
- ❌ **DFTX** (2026-08-11) drop:-8.9% → Day30:-8.0% [-] conf:74% Markets are pricing in high probability
- ❌ **ALMS** (2026-08-11) drop:-8.2% → Day30:-60.7% [-] conf:78% 市场将积极临床 data（54% complete clearance at 4
- ✅ **TEO** (2026-08-11) drop:-7.0% → Day30:+0.8% [-] conf:78% Market interpreted Q2 earnings release a
- ❌ **APP** (2026-08-11) drop:-5.6% → Day30:-0.8% [-] conf:72% AppLovin’s Q2 revenue miss and rising ex
- ✅ **BRVE** (2026-08-11) drop:-9.2% → Day30:+8.3% [-] conf:72% 市场因信息真空与流动性扰动对BRVE进行无差别抛售，叠加小盘生物科技股在弱市中被
- ✅ **WRD** (2026-08-12) drop:-9.7% → Day30:+0.3% [-] conf:78% 市场因WRD Q2 2026财报‘EPS flat despite 92% Yo
- ✅ **GRAL** (2026-08-12) drop:-8.6% → Day30:+10.7% [-] conf:72% 市场将GRAL与Guardant Health（GH）的正面MRD/screen
- ❌ **LQDA** (2026-08-12) drop:-8.4% → Day30:-16.0% [-] conf:76% Market interpreted Q2 earnings as weak d
- ❌ **NYAX** (2026-08-12) drop:-6.4% → Day30:-5.3% [-] conf:68% Barclays downgraded price target by $7 (
- ✅ **GENVR** (2026-08-12) drop:-6.5% → Day30:+23.1% [-] conf:58% 市场因信息真空与流动性恐慌抛售GENVR, 暗示潜在未披露风险或基本面恶化。
- ❌ **BSP** (2026-08-12) drop:-8.3% → Day30:-20.3% [-] conf:74% Market perceives BSP as overvalued and f
- ❌ **LIME** (2026-08-12) drop:-6.9% → Day30:-15.6% [-] conf:78% Market conflates LIME (Neutron Holdings)
- ✅ **SNAP** (2026-08-12) drop:-5.6% → Day30:+9.1% [-] conf:74% Snap is materially exposed to escalating
- ✅ **CLBT** (2026-08-13) drop:-33.4% → Day29:+10.8% [-] conf:74% CLBT plunged 33% on Q2 revenue miss and
- ❌ **LFTO** (2026-08-13) drop:-18.7% → Day29:-10.0% [-] conf:78% LFTO plunged on Q2 2026 earnings despite
- ❌ **BSP** (2026-08-13) drop:-17.1% → Day29:-3.9% [-] conf:78% Despite a strong Q2 EPS beat (+70% vs es
- ✅ **BLTE** (2026-08-13) drop:-8.5% → Day29:+5.8% [-] conf:78% 市场将FDA授予Tinlarebant优先审评（重大利好）与Q2亏损扩大（-8%
- ❌ **CW** (2026-08-13) drop:-5.4% → Day29:-18.3% [-] conf:78% Market is pricing in unexplained negativ
- ❌ **LQDA** (2026-08-13) drop:-8.5% → Day29:-6.1% [-] conf:72% 市场因分析师评级分歧（LifeSci downgrade amid multip
- ❌ **KOD** (2026-08-13) drop:-7.9% → Day29:-18.1% [-] conf:74% 市场将Q2净亏损$65.6M（同比扩大）和现金余额$125.9M解读为财务压力加
- ✅ **GENVR** (2026-08-14) drop:-16.2% → Day28:+33.8% [-] conf:72% 市场因不明负面事件恐慌抛售Gen Digital，叠加流动性枯竭（成交量骤降91
- ✅ **VCRE** (2026-08-14) drop:-12.9% → Day28:+0.9% [-] conf:72% 市场因不明负面事件或 liquidity-driven panic sellin
- ❌ **UCTT** (2026-08-14) drop:-8.1% → Day28:-13.2% [-] conf:78% Market interpreted the $400M ATM equity
- ✅ **WIX** (2026-08-14) drop:-7.3% → Day28:+3.5% [-] conf:72% Market is pricing in litigation risk and
- ❌ **LIME** (2026-08-14) drop:-6.3% → Day28:-14.8% [-] conf:78% Market is pricing in undisclosed negativ
- ✅ **DOCS** (2026-08-14) drop:-6.0% → Day28:+2.7% [-] conf:72% 市场在消化DOCS近期暴涨后的获利回吐，叠加对AI叙事可持续性的短期怀疑，但无明
- ❌ **HAWK** (2026-08-14) drop:-5.2% → Day28:-29.3% [-] conf:78% Despite beating EPS and revenue estimate
- ✅ **DUOL** (2026-08-14) drop:-7.8% → Day28:+9.1% [-] conf:78% Market is punishing DUOL for the Animade
- ✅ **PGEN** (2026-08-14) drop:-6.0% → Day28:+12.9% [-] conf:72% Precigen’s recent sharp rally has made s
- ✅ **GENVR** (2026-08-17) drop:-23.6% → Day30:+94.5% [-] conf:72% 市场因不明负面催化剂集体抛售GENVR, 暗示存在未披露的重大风险或流动性危机
- ✅ **CLOV** (2026-08-17) drop:-7.9% → Day30:+7.9% [-] conf:78% 市场因Q2 2026 earnings call interpreting 'b
- ❌ **LFTO** (2026-08-17) drop:-9.5% → Day30:-11.5% [-] conf:72% 市场因不明负面催化剂集体抛售LFTO，叠加板块疲软，形成恐慌性超调；叙事缺失具体
- ✅ **TENB** (2026-08-17) drop:-6.9% → Day30:+1.6% [-] conf:72% 市场因缺乏明确负面催化剂而恐慌性抛售，叠加机构持仓分歧（Firetrail bu
- ✅ **FA** (2026-08-17) drop:-6.8% → Day30:+6.7% [-] conf:72% 市场因不明负面催化剂抛售FA，叠加超调情绪，但无实质性利空信息支撑
- ❌ **IRTC** (2026-08-17) drop:-6.9% → Day30:-4.8% [-] conf:72% 市场因‘法律调查’和‘内幕交易/信义义务质疑’传闻恐慌性抛售，将未证实的监管风险
- ✅ **CLBT** (2026-08-17) drop:-5.6% → Day30:+9.1% [-] conf:72% 市场因分析师降级和‘增长前景黯淡’叙事抛售CLBT，认为其核心执法软件业务面临需
- ❌ **RDDT** (2026-08-17) drop:-6.4% → Day30:-5.6% [-] conf:78% Reddit sold off alongside broader market
- ❌ **VNET** (2026-08-18) drop:-17.3% → Day30:-6.0% [-] conf:78% VNET reported Q2 EPS $(0.06) — inline bu
- ❌ **BIDU** (2026-08-18) drop:-12.8% → Day30:-0.8% [-] conf:74% Baidu missed Q2 EPS by 21.5% and revenue
- ✅ **MXL** (2026-08-18) drop:-14.8% → Day30:+4.8% [-] conf:72% Market is punishing MXL for 'valuation e
- ✅ **AUR** (2026-08-18) drop:-11.7% → Day30:+6.0% [-] conf:74% Aurora's stock plunged on news that riva
- ✅ **ACHC** (2026-08-18) drop:-8.0% → Day30:+4.1% [-] conf:78% 市场因不明负面催化剂抛售ACHC，叠加异常放量，暗示恐慌性出清或做空驱动，但无实
- ✅ **TWST** (2026-08-18) drop:-7.0% → Day30:+36.4% [-] conf:78% 市场将 insider 大额股票出售与公司基本面恶化、以及近期 Upsized
- ❌ **AEIS** (2026-08-18) drop:-9.9% → Day30:-19.6% [-] conf:72% Market is pricing in unannounced negativ
- ✅ **TIGO** (2026-08-18) drop:-8.1% → Day30:+10.1% [-] conf:78% JPMorgan downgraded TIGO to Neutral citi
- ❌ **LCID** (2026-08-18) drop:-7.1% → Day30:-25.4% [-] conf:72% Market is punishing LCID as part of a br
- ❌ **VRT** (2026-08-18) drop:-6.7% → Day30:-11.3% [-] conf:78% Market is pricing in material risk from
- ❌ **AAOI** (2026-08-18) drop:-15.2% → Day30:-25.5% [-] conf:74% AAOI sold off violently as part of a bro
- ❌ **NBIS** (2026-08-18) drop:-7.6% → Day30:-13.3% [-] conf:68% Market is punishing NBIS on unexplained,
- ❌ **MRCY** (2026-08-18) drop:-7.4% → Day30:-17.6% [-] conf:78% MRCY missed Q4 EPS by $0.01 (reported $0
- ✅ **NBIS** (2026-08-19) drop:-12.0% → Day30:+1.3% [-] conf:78% Market interpreted Nebius's $4.5B conver
- ✅ **VICR** (2026-08-19) drop:-11.3% → Day30:+2.2% [-] conf:78% 市场将董事小幅减持（908股）与‘ insider selling’标签化解读为
- ❌ **FSLY** (2026-08-19) drop:-10.0% → Day30:-0.6% [-] conf:78% Despite beating EPS estimates and raisin
- ❌ **AEIS** (2026-08-19) drop:-6.4% → Day30:-11.3% [-] conf:72% AEIS plunged -6.36% on unexplained weakn
- ❌ **CBOE** (2026-08-19) drop:-5.2% → Day30:-2.8% [-] conf:74% Cboe is losing relevance as new entrants
- ❌ **AXTI** (2026-08-19) drop:-10.8% → Day30:-4.4% [-] conf:78% AXTI plunged on unconfirmed earnings dis
- ✅ **MRNA** (2026-08-20) drop:-22.8% → Day29:+15.0% [-] conf:78% Moderna collapsed inexplicably amid broa
- ✅ **SHAZ** (2026-08-20) drop:-10.7% → Day29:+0.8% [-] conf:78% Market interprets the 8-K filing as nega
- ❌ **KC** (2026-08-20) drop:-6.8% → Day29:-13.8% [-] conf:78% Despite strong Q2 results (revenue +30.8
- ❌ **SEPN** (2026-08-20) drop:-7.9% → Day29:-5.3% [-] conf:72% 市场因信息真空和流动性萎缩对SEPN产生无差别抛压，叠加板块疲软引发技术性踩踏，
- ❌ **MRCY** (2026-08-20) drop:-6.9% → Day29:-9.9% [-] conf:78% Market punished MRCY for 'mixed' Q4 resu
- ❌ **LFTO** (2026-08-20) drop:-5.6% → Day29:-10.8% [-] conf:72% Market is pricing in deteriorating funda
- ❌ **NTES** (2026-08-20) drop:-5.3% → Day29:-3.5% [-] conf:76% NetEase missed Q2 EPS by 22.4% ($1.77 vs
- ✅ **SPCX** (2026-08-20) drop:-5.0% → Day29:+15.0% [-] conf:78% SpaceX stock is collapsing due to the se
- ✅ **TLX** (2026-08-21) drop:-8.7% → Day28:+11.5% [-] conf:72% Market interpreted TLX's Q2 earnings and
- ✅ **IOVA** (2026-08-21) drop:-7.4% → Day28:+22.5% [-] conf:72% 市场在连续多日强势上涨（包括52-week high、'best day in
- ❌ **OSIS** (2026-08-21) drop:-8.5% → Day28:-0.7% [-] conf:74% OSIS plunged on mixed Q4 results and FY2
- ❌ **CBRS** (2026-08-21) drop:-5.5% → Day28:-0.2% [-] conf:72% CBRS tumbled on a 'mixed' Q1 print and m
- ✅ **MRVL** (2026-08-21) drop:-5.6% → Day28:+0.7% [-] conf:72% MRVL is selling off ahead of Q3 earnings
- ✅ **AUR** (2026-08-24) drop:-8.6% → Day30:+10.1% [-] conf:62% Market is pricing in fundamental deterio
- ❌ **HIMS** (2026-08-24) drop:-8.5% → Day30:-6.9% [-] conf:78% HIMS is crashing due to an FTC lawsuit a
- ❌ **VCRE** (2026-08-24) drop:-8.4% → Day30:-14.4% [-] conf:68% 市场因缺乏明确负面催化剂而恐慌性抛售，可能误读即将披露的360+患者肺部试验数据
- ❌ **RGTI** (2026-08-24) drop:-8.0% → Day30:-2.0% [-] conf:72% Quantum computing stocks are unwinding a
- ❌ **BZ** (2026-08-24) drop:-5.4% → Day30:-4.1% [-] conf:78% 市场将Kanzhun（BZ）与无关的‘BZ’股票（如Benz Mining AS
- ❌ **LCID** (2026-08-24) drop:-5.9% → Day30:-19.6% [-] conf:72% LCID plunged to a 52-week low on wider-t
- ✅ **TEM** (2026-08-24) drop:-9.0% → Day30:+15.0% [-] conf:78% Market interpreted FDA clearance for Tem
- ❌ **DPC** (2026-08-24) drop:-5.8% → Day30:-2.1% [-] conf:72% 市场将新机构建仓误读为利好兑现或内幕知情抛压，叠加板块弱势引发流动性踩踏。
- ❌ **HAWK** (2026-08-24) drop:-5.2% → Day30:-22.0% [-] conf:78% 市场将'Hawk Fire'（内华达野火）与HawkEye 360公司名称中的'
- ✅ **RBRK** (2026-08-25) drop:-6.3% → Day30:+24.6% [-] conf:68% Market is selling off Rubrik ahead of ea
- ❌ **ALB** (2026-08-25) drop:-6.1% → Day30:-18.1% [-] conf:72% JP Morgan downgraded ALB to Neutral and
- ❌ **GENVR** (2026-08-25) drop:-6.7% → Day30:-61.1% [-] conf:78% 市场因信息真空与代码混淆（GENVR vs. GEN）产生恐慌性抛售，误将无关技
- ✅ **MMED** (2026-08-25) drop:-5.1% → Day30:+7.9% [-] conf:68% 市场因不明负面事件或流动性抛压对MMED进行无差别抛售，叠加小市值医疗器械股的脆
- ❌ **GENB** (2026-08-26) drop:-19.7% → Day30:-6.8% [-] conf:78% GENB股价暴跌近20%因锁定期结束，市场恐慌性抛售1.03亿股解禁股份，担忧短
- ❌ **SYRE** (2026-08-26) drop:-11.3% → Day30:-9.6% [-] conf:78% SYRE's SKYWAY Phase 2b study in rheumato
- ❌ **QBTS** (2026-08-26) drop:-9.0% → Day30:-0.8% [-] conf:72% 市场将CFO退休解读为公司治理不稳定、财务透明度风险上升，叠加量子计算行业短期盈
- ❌ **RUM** (2026-08-26) drop:-8.5% → Day30:-10.6% [-] conf:78% 市场将RUM的-8.46%单日下跌解读为AI云利好兑现后的‘利好出尽’和获利回吐
- ❌ **SNAP** (2026-08-26) drop:-7.8% → Day30:-0.2% [-] conf:74% Snap is facing escalating state litigati
- ❌ **ZM** (2026-08-26) drop:-6.6% → Day30:-4.7% [-] conf:74% Zoom beat Q2 EPS and revenue but issued
- ❌ **LCID** (2026-08-26) drop:-6.6% → Day30:-17.8% [-] conf:72% Lucid stock plunged on fears that Trump’
- ✅ **P** (2026-08-27) drop:-10.3% → Day29:+28.0% [-] conf:78% Despite strong Q2 results and major guid
- ❌ **PHI** (2026-08-27) drop:-7.8% → Day29:-4.5% [-] conf:72% PHI sold off sharply on broad Philippine
- ✅ **MRNA** (2026-08-27) drop:-6.2% → Day29:+41.6% [-] conf:76% Moderna’s $2B convertible note offering
- ❌ **BHVN** (2026-08-27) drop:-5.4% → Day29:-18.6% [-] conf:82% 市场误将前一日大幅上涨后的正常获利回吐解读为负面信号，叠加板块拖累引发超调；实际
- ❌ **VERA** (2026-08-27) drop:-6.0% → Day29:-5.0% [-] conf:78% 市场将Vera Therapeutics的下跌错误归因于 broader bio
- ❌ **MRVI** (2026-08-27) drop:-6.0% → Day29:-11.4% [-] conf:68% Maravai's sharp drop reflects profit-tak
- ✅ **SHAZ** (2026-08-28) drop:-13.3% → Day28:+6.0% [-] conf:74% Nvidia halted financing and paused reven
- ❌ **SLS** (2026-08-28) drop:-11.5% → Day28:-14.2% [-] conf:72% Market interpreted recent bullish cataly
- ✅ **HIMS** (2026-08-28) drop:-9.6% → Day28:+2.8% [-] conf:74% Market is pricing in material regulatory
- ✅ **COIN** (2026-08-28) drop:-6.4% → Day28:+9.5% [-] conf:72% Coinbase fell sharply on broad rate-hike
- ❌ **RIVN** (2026-08-28) drop:-5.2% → Day28:-3.7% [-] conf:78% CFO departure signals leadership instabi
- ❌ **KLRA** (2026-08-28) drop:-12.5% → Day28:-31.0% [-] conf:72% KLRA plunged 12.5% on unexplained, non-c
- ✅ **RBRK** (2026-08-28) drop:-13.1% → Day28:+18.0% [-] conf:74% Rubrik plunged -13% despite no negative
- ✅ **HOOD** (2026-08-28) drop:-5.0% → Day28:+14.4% [-] conf:72% Market is pricing in unexplained weaknes
- ❌ **PL** (2026-08-28) drop:-5.6% → Day28:-13.0% [-] conf:68% Market is pricing in unannounced negativ
- ❌ **HAWK** (2026-08-28) drop:-5.3% → Day28:-16.6% [-] conf:72% Market conflated HawkEye 360 (HAWK) with
- ❌ **KLRA** (2026-08-31) drop:-17.4% → Day30:-25.8% [-] conf:72% 市场将KLRA归类为‘broken biotech’并恐慌性抛售 amid no
- ❌ **SLS** (2026-08-31) drop:-13.7% → Day30:-5.6% [-] conf:72% Market interprets BMF Capital's short di
- ✅ **RBRK** (2026-08-31) drop:-14.1% → Day30:+25.7% [-] conf:78% Rubrik beat EPS and raised FY27 ARR guid
- ✅ **MRVL** (2026-08-31) drop:-12.6% → Day30:+25.0% [-] conf:78% Marvell sold off sharply due to hawkish
- ✅ **NBIS** (2026-08-31) drop:-6.5% → Day30:+15.4% [-] conf:72% Nebius is overvalued after a 120% rally
- ❌ **TKC** (2026-08-31) drop:-6.4% → Day30:-1.9% [-] conf:72% Turkcell is being punished for an index
- ✅ **DPC** (2026-08-31) drop:-7.7% → Day30:+1.5% [-] conf:62% Market is pricing in unannounced negativ
- ❌ **RIVN** (2026-08-31) drop:-5.1% → Day30:-6.0% [-] conf:72% Rivian CFO departure amid R2 launch unce
- ❌ **HAWK** (2026-08-31) drop:-7.6% → Day30:-19.3% [-] conf:78% 市场将早期锁定期解禁（9月2日）和Russell 2000纳入（prelimin
- ❌ **ONDS** (2026-08-31) drop:-12.5% → Day30:-3.7% [-] conf:78% Market interprets Q2 $50.6M loss and ins
- ✅ **TEM** (2026-08-31) drop:-10.8% → Day30:+31.4% [-] conf:72% 市场因不明负面催化剂抛售TEM，叠加板块疲软，形成恐慌性超调；叙事模糊，无明确财
- ✅ **GLBE** (2026-08-31) drop:-5.4% → Day30:+6.6% [-] conf:72% Market is punishing GLBE on vague 'insid
- ❌ **TTWO** (2026-08-31) drop:-5.7% → Day30:-5.0% [-] conf:62% GTA VI leak has resurfaced and is spooki
- ❌ **PL** (2026-08-31) drop:-6.2% → Day30:-16.4% [-] conf:68% Planet Labs is in a 'bear market' ahead
- ❌ **ALMS** (2026-09-01) drop:-56.9% → Day30:-22.7% [-] conf:78% ALMS plunged 57% after releasing Phase I
- ❌ **ADBT** (2026-09-01) drop:-17.2% → Day30:-96.2% [-] conf:72% ADBT sold off sharply alongside broad ma
- ❌ **GENVR** (2026-09-01) drop:-9.4% → Day30:-83.2% [-] conf:72% 市场因不明负面催化剂抛售GENVR despite positive insti
- ✅ **RGEN** (2026-09-01) drop:-6.9% → Day30:+6.9% [-] conf:74% Market is pricing in broad-based 'growth
- ✅ **FROG** (2026-09-01) drop:-8.6% → Day30:+7.8% [-] conf:72% Market is punishing FROG for insider sel
- ❌ **BYND** (2026-09-01) drop:-6.3% → Day30:-33.6% [-] conf:72% 市场将BYND的大幅下跌归因为基本面持续恶化、行业竞争加剧及长期增长失速，但无具
- ✅ **COIN** (2026-09-01) drop:-5.8% → Day30:+6.9% [-] conf:72% Crypto stocks are collapsing despite fla
- ❌ **RUM** (2026-09-01) drop:-5.1% → Day30:-8.8% [-] conf:62% 市场将RUM与AI算力军备竞赛叙事捆绑，担忧其Quake AI项目缺乏客户验证、
- ❌ **LCID** (2026-09-01) drop:-5.4% → Day30:-8.8% [-] conf:72% LCID is collapsing because it's 'a penny
- ✅ **FSLY** (2026-09-01) drop:-8.9% → Day30:+27.9% [-] conf:72% Market is punishing FSLY as a 'weak clou
- ❌ **ERAS** (2026-09-01) drop:-6.3% → Day30:-13.0% [-] conf:72% ERAS stock collapsed nearly 40% after-ho
- ✅ **MRCY** (2026-09-01) drop:-5.2% → Day30:+0.9% [-] conf:68% 市场因信息真空和板块超跌情绪抛售MRCY，隐含担忧订单可持续性或国防预算风险，但
- ❌ **ADBT** (2026-09-02) drop:-54.6% → Day30:-91.5% [-] conf:72% Market interpreted CEO stepping into int
- ✅ **CRDO** (2026-09-02) drop:-20.4% → Day30:+33.3% [-] conf:78% CRDO plunged 20% despite beating EPS and
- ❌ **OMC** (2026-09-02) drop:-5.5% → Day30:-9.0% [-] conf:72% Market is punishing OMC for unexplained
- ❌ **BYND** (2026-09-02) drop:-6.7% → Day30:-29.8% [-] conf:78% Market is punishing BYND on vague regula
- ✅ **BFLY** (2026-09-02) drop:-6.0% → Day30:+14.6% [-] conf:74% 市场将Merge Labs授权合作误读为技术变现受阻、商业化路径稀释或核心IP被
- ✅ **DPC** (2026-09-02) drop:-6.2% → Day30:+7.0% [-] conf:72% 市场因信息真空与行业联想（航天防务板块受宏观情绪扰动）而抛售DPC, 但无任何与
- ❌ **ADBT** (2026-09-03) drop:-80.5% → Day29:-58.0% [-] conf:72% Market interpreted CFO departure as a si
- ✅ **RARE** (2026-09-03) drop:-44.3% → Day29:+2.7% [-] conf:72% Ultragenyx's stock collapsed due to a cl
- ✅ **CIEN** (2026-09-03) drop:-11.5% → Day29:+25.6% [-] conf:78% Ciena delivered a record quarter with st
- ❌ **PL** (2026-09-03) drop:-9.6% → Day29:-2.5% [-] conf:78% Market interprets PL's 8% drop as earnin
- ❌ **LIME** (2026-09-03) drop:-6.0% → Day29:-30.4% [-] conf:78% 市场因混淆LIME（Neutron Holdings）与USLM（United
- ❌ **CHTR** (2026-09-03) drop:-5.4% → Day29:-27.5% [-] conf:74% Market is punishing CHTR for CFO transit
- ❌ **IONS** (2026-09-03) drop:-6.2% → Day29:-24.6% [-] conf:72% Market is pricing in broad biotech pipel
- ✅ **APH** (2026-09-04) drop:-47.9% → Day28:+5.8% [-] conf:78% 市场因未披露的重大负面事件（如突发性大客户流失、供应链断裂或监管突袭）而恐慌抛售
- ❌ **GWRE** (2026-09-04) drop:-20.4% → Day28:-6.1% [-] conf:72% GWRE delivered a strong fiscal Q4 (beat
- ❌ **GENVR** (2026-09-04) drop:-10.3% → Day28:-81.5% [-] conf:72% 市场因不明负面催化剂抛售GENVR, 暗示存在未披露的重大风险或即将发生的负面事
- ✅ **TSLA** (2026-09-04) drop:-5.8% → Day28:+5.2% [-] conf:74% Cybercab launch underwhelmed investors a
- ❌ **RUM** (2026-09-04) drop:-5.2% → Day28:-12.6% [-] conf:68% Rumble is losing momentum in the alterna
- ❌ **LIME** (2026-09-04) drop:-5.4% → Day28:-25.9% [-] conf:78% Market conflates Neutron Holdings (LIME)
- ❌ **NFLX** (2026-09-04) drop:-5.3% → Day28:-14.2% [-] conf:74% Netflix’s UK price hike is triggering su
- ❌ **DJT** (2026-09-04) drop:-5.2% → Day28:-1.8% [-] conf:72% Trump Media is collapsing due to a newly
- ❌ **FICO** (2026-09-04) drop:-16.7% → Day28:-29.4% [-] conf:78% FHFA Director Bill Pulte declared FICO's
- ❌ **GENVR** (2026-09-08) drop:-13.6% → Day30:-78.6% [-] conf:72% 市场因信息真空与流动性恐慌抛售GENVR, 暗示存在未披露的重大负面事件或财务恶
- ❌ **DYN** (2026-09-08) drop:-15.3% → Day30:-20.4% [-] conf:72% 市场将DYN的大幅下跌归因于 unconfirmed negative cata
- ✅ **NVS** (2026-09-08) drop:-14.1% → Day30:+4.1% [-] conf:74% Novartis’ -14% crash reflects market pan
- ✅ **APPN** (2026-09-08) drop:-9.4% → Day30:+10.6% [-] conf:74% 市场将Appian的大幅下跌归因于 unexplained weakness a
- ❌ **PATH** (2026-09-08) drop:-7.8% → Day30:-5.5% [-] conf:72% UiPath beat Q2 EPS and raised full-year
- ❌ **BIDU** (2026-09-08) drop:-7.3% → Day30:-9.3% [-] conf:72% Baidu’s sharp drop reflects confusion an
- ✅ **PRCH** (2026-09-08) drop:-6.9% → Day30:+2.6% [-] conf:72% 市场因缺乏明确负面催化剂而对PRCH进行流动性折价抛售，叠加板块弱势引发技术性踩
- ❌ **GPCR** (2026-09-08) drop:-14.7% → Day30:-36.1% [-] conf:78% Market interpreted recent obesity trial
- ✅ **GDDY** (2026-09-08) drop:-8.3% → Day30:+11.3% [-] conf:78% Market is pricing in material near-term
- ✅ **TTAN** (2026-09-09) drop:-29.5% → Day30:+26.9% [-] conf:72% ServiceTitan plunged 29.5% after reporti
- ✅ **BRZE** (2026-09-09) drop:-20.8% → Day30:+20.9% [-] conf:78% Braze beat Q2 EPS and revenue but cut Q3
- ✅ **RGC** (2026-09-09) drop:-13.3% → Day30:+24.4% [-] conf:68% 市场因‘法律与亏损担忧’（TipRanks标题）对RGC产生恐慌性抛售，暗示存在
- ❌ **NAMS** (2026-09-09) drop:-11.2% → Day30:-6.3% [-] conf:72% NAMS sold off sharply due to sector-wide
- ❌ **RUM** (2026-09-09) drop:-9.2% → Day30:-8.2% [-] conf:68% 市场在高位获利了结，担忧33%单月涨幅不可持续，叠加AI概念估值过热引发抛压。
- ❌ **VRT** (2026-09-09) drop:-9.9% → Day30:-7.1% [-] conf:78% 市场将Vertiv收购UtilityInnovation（UIG）的$1.45B
- ❌ **LIME** (2026-09-09) drop:-9.3% → Day30:-16.8% [-] conf:76% 市场因不明负面消息抛售LIME，可能误读Neutron相关进展或混淆主体（如将R
- ✅ **PINS** (2026-09-09) drop:-7.8% → Day30:+15.0% [-] conf:72% Market is pricing in structural deterior
- ❌ **LCID** (2026-09-09) drop:-7.7% → Day30:-11.8% [-] conf:68% Lucid is in irreversible decline due to
- ✅ **NAVN** (2026-09-10) drop:-21.6% → Day29:+15.7% [-] conf:74% Market punished NAVN despite strong Q2 e
- ❌ **BHVN** (2026-09-10) drop:-13.3% → Day29:-6.8% [-] conf:78% FDA imposed a partial clinical hold on B
- ❌ **COO** (2026-09-10) drop:-12.9% → Day29:-1.7% [-] conf:78% COO missed Q3 revenue expectations due t
- ❌ **LBTYB** (2026-09-10) drop:-5.3% → Day29:-2.8% [-] conf:78% 市场将Allianz减持解读为机构看衰LBTYB基本面或流动性风险信号，暗示潜在
- ✅ **FDS** (2026-09-10) drop:-5.3% → Day29:+8.1% [-] conf:74% FactSet is being punished as a 'legacy f
- ❌ **VRT** (2026-09-10) drop:-5.7% → Day29:-1.8% [-] conf:68% Vertiv is suffering a sharp, unexplained
- ❌ **CRWV** (2026-09-10) drop:-5.8% → Day29:-8.3% [-] conf:74% CoreWeave is collapsing because Burry’s
- ❌ **LFTO** (2026-09-10) drop:-5.1% → Day29:-12.9% [-] conf:62% Market interprets initiation with Hold r
- ✅ **HPE** (2026-09-10) drop:-6.2% → Day29:+32.9% [-] conf:72% HPE is unwinding recent AI server moment
- ❌ **SLS** (2026-09-11) drop:-13.2% → Day28:-0.7% [-] conf:72% 市场因传闻性监管调查和临床数据延迟担忧抛售SLS，叠加短期多头获利了结，叙事聚焦
- ✅ **DOCN** (2026-09-11) drop:-6.7% → Day28:+10.2% [-] conf:78% 市场将重大利好融资公告（$725M equipment facility）误读为
- ✅ **QLYS** (2026-09-11) drop:-5.5% → Day28:+32.0% [-] conf:72% Wedbush downgraded QLYS to Neutral with
- ❌ **RCUS** (2026-09-11) drop:-6.1% → Day28:-0.9% [-] conf:72% Arcus's lead cancer drug (zimberelimab +
- ❌ **KLRA** (2026-09-11) drop:-6.5% → Day28:-16.6% [-] conf:62% Market is pricing in deteriorating funda
- ❌ **SIMO** (2026-09-14) drop:-14.7% → Day30:-7.5% [-] conf:78% SIMO sold off sharply amid broad-based A
- ❌ **GLW** (2026-09-14) drop:-13.5% → Day30:-1.7% [-] conf:78% Corning’s $2B at-the-market (ATM) equity
- ✅ **AEIS** (2026-09-14) drop:-10.1% → Day30:+1.2% [-] conf:72% AEIS sold off sharply amid broad-based A
- ✅ **BZ** (2026-09-14) drop:-6.0% → Day30:+5.8% [-] conf:72% 市场因不明原因抛售BZ，叠加领导层轮换传闻引发估值担忧和流动性恐慌。
- ❌ **SRRK** (2026-09-14) drop:-6.1% → Day30:-23.8% [-] conf:78% Market misinterpreted FDA approval of IS
- ❌ **NBIS** (2026-09-14) drop:-5.1% → Day30:-13.6% [-] conf:72% Nebius is being punished as a 'rented co
- ❌ **IONS** (2026-09-14) drop:-5.1% → Day30:-17.2% [-] conf:72% Market is pricing in broad biotech secto
- ❌ **VRT** (2026-09-14) drop:-7.0% → Day30:-7.1% [-] conf:72% Vertiv sold off sharply amid AI infrastr
- ❌ **DLR** (2026-09-14) drop:-5.0% → Day30:-3.5% [-] conf:72% Market is pricing in AI infrastructure d
- ❌ **ALHC** (2026-09-15) drop:-22.1% → Day30:-18.3% [-] conf:72% Market is punishing ALHC for perceived r
- ❌ **ARWR** (2026-09-15) drop:-11.8% → Day30:-18.0% [-] conf:78% Market interpreted positive Phase 1/2a i
- ✅ **COIN** (2026-09-15) drop:-9.0% → Day30:+5.6% [-] conf:72% Coinbase plunged on fading near-term odd
- ✅ **PCOR** (2026-09-15) drop:-6.5% → Day30:+10.2% [-] conf:72% 市场将董事长减持解读为负面信号，叠加板块轮动中个股被错杀，误读为基本面恶化或信心
- ✅ **ULS** (2026-09-15) drop:-5.5% → Day30:+13.3% [-] conf:72% ULS is falling with the broader market a
- ❌ **GENVR** (2026-09-15) drop:-7.5% → Day30:-80.6% [-] conf:78% 市场将GENVR的-7.46%单日跌幅错误归因为个股风险，实则为大盘与板块普跌背
- ✅ **STRK** (2026-09-15) drop:-6.1% → Day30:+4.1% [-] conf:72% Strategy (STRK) is punished for pausing
- ❌ **SLNHP** (2026-09-15) drop:-5.6% → Day30:+nan% [-] conf:74% 市场因SEC 8-K文件突发披露而恐慌性抛售，猜测存在重大不利事件（如内控缺陷、
- ❌ **ALHC** (2026-09-16) drop:-16.7% → Day30:-4.3% [-] conf:72% ALHC is collapsing due to perceived mate
- ❌ **PLSE** (2026-09-16) drop:-10.2% → Day30:-10.0% [-] conf:78% Market interpreted the at-the-market (AT
- ✅ **ON** (2026-09-16) drop:-7.3% → Day30:+6.4% [-] conf:72% ON Semiconductor sold off sharply alongs
- ✅ **SYNA** (2026-09-16) drop:-7.1% → Day30:+29.7% [-] conf:78% 市场将SYNA的-7.09%大跌错误归因为负面事件，实则无实质性利空；部分社交平
- ❌ **HOOD** (2026-09-16) drop:-7.1% → Day30:-4.3% [-] conf:76% 市场将两名前Robinhood工程师被联邦起诉的事件错误归因为Robinhood
- ✅ **TKC** (2026-09-16) drop:-5.5% → Day30:+0.3% [-] conf:72% Turkcell plunged due to broad Turkish ma
- ❌ **LFTO** (2026-09-16) drop:-5.5% → Day30:-4.5% [-] conf:62% 市场因信息真空与板块情绪共振，将LFTO归类为‘adtech脆弱性标的’而抛售，
- ✅ **COIN** (2026-09-16) drop:-5.6% → Day30:+5.3% [-] conf:72% COIN plunged because the CLARITY Act fai
- ✅ **RBLX** (2026-09-16) drop:-5.6% → Day30:+4.2% [-] conf:62% Roblox is selling off on profit-taking a
- ✅ **TTAN** (2026-09-17) drop:-6.7% → Day29:+36.7% [-] conf:78% Market is pricing in material revenue ti
- ❌ **FLUT** (2026-09-17) drop:-5.6% → Day29:-18.2% [-] conf:62% Kenneth Dart — a major shareholder and p
- ✅ **DVA** (2026-09-17) drop:-5.5% → Day29:+2.2% [-] conf:72% 市场将DVA的下跌归因为医疗板块疲软或大盘波动，但实际SPY和XLV均上涨，个股
- ❌ **TMUS** (2026-09-17) drop:-5.4% → Day29:-5.0% [-] conf:78% Market interpreted Q2 2026 earnings call
- ❌ **GENVR** (2026-09-17) drop:-5.2% → Day29:-75.5% [-] conf:58% Market perceives Gen Digital as underper
- ❌ **NVST** (2026-09-17) drop:-5.1% → Day29:-3.1% [-] conf:72% 市场将 Investor Day 和8-K文件误读为负面催化剂，暗示隐含利空（如
- ❌ **XENE** (2026-09-18) drop:-30.5% → Day28:-15.5% [-] conf:72% XENE’s -30.5% crash reflects market pani
- ❌ **GENVR** (2026-09-18) drop:-13.3% → Day28:-71.8% [-] conf:68% Market is pricing in severe, unexplained
- ✅ **KD** (2026-09-18) drop:-6.7% → Day28:+9.3% [-] conf:68% Market is pricing in deteriorating funda
- ✅ **FIVN** (2026-09-18) drop:-6.5% → Day28:+0.2% [-] conf:72% 市场将FIVN归类为‘software sector contagion sel
- ❌ **ALKS** (2026-09-18) drop:-6.1% → Day28:-5.6% [-] conf:72% 市场因不明负面事件（可能与SEC 8-K相关）担忧监管风险或 undisclos
- ✅ **LFTO** (2026-09-18) drop:-5.5% → Day28:+0.1% [-] conf:58% 市场因不明负面消息（疑似内幕交易传闻或未披露的业务风险）对LFTO进行抛售，叠加
- ✅ **TNGX** (2026-09-18) drop:-7.4% → Day28:+1.8% [-] conf:62% Market is pricing in undisclosed negativ
- ❌ **BRVE** (2026-09-21) drop:-13.9% → Day25:-26.7% [-] conf:62% Market is pricing in unannounced negativ
- ❌ **PBLS** (2026-09-21) drop:-12.7% → Day25:-35.2% [-] conf:62% 市场因不明负面催化剂集体抛售PBLS, interpreting the -12
- ❌ **HPQ** (2026-09-21) drop:-5.1% → Day25:-8.1% [-] conf:72% HPQ is pricing in a structural, multi-ye
- ❌ **GENVR** (2026-09-22) drop:-38.9% → Day24:-52.0% [-] conf:78% Market is pricing in severe, unexplained
- ❌ **XNDU** (2026-09-22) drop:-21.9% → Day24:-47.0% [-] conf:68% Market is pricing in a fundamental deter
- ❌ **WGS** (2026-09-22) drop:-10.1% → Day24:-28.2% [-] conf:72% 市场担忧GeneDx免费罕见病检测项目可能引发监管审查、商业模式可持续性危机及盈
- ❌ **NKTR** (2026-09-22) drop:-9.8% → Day24:-40.4% [-] conf:72% Market is punishing NKTR on vague 'index
- ❌ **GEN** (2026-09-22) drop:-7.6% → Day24:-10.7% [-] conf:72% GEN plunged 7.6% amid vague 'S&P500 lose
- ✅ **LFTO** (2026-09-22) drop:-7.0% → Day24:+0.4% [-] conf:62% Market interprets Piper Sandler's Neutra
- ✅ **PINS** (2026-09-22) drop:-5.3% → Day24:+19.9% [-] conf:62% Pinterest is collapsing due to a mysteri
- ❌ **CLDX** (2026-09-22) drop:-11.6% → Day24:-17.5% [-] conf:78% Market interpreted positive Phase 3 barz
- ✅ **BSP** (2026-09-22) drop:-6.8% → Day24:+29.6% [-] conf:78% Market conflated Bending Spoons (BSP) wi
- ❌ **TTD** (2026-09-22) drop:-5.0% → Day24:-7.1% [-] conf:78% TTD’s Q2 results revealed weak growth, m
- ❌ **CLDX** (2026-09-23) drop:-18.9% → Day23:-10.0% [-] conf:78% Market misinterpreted positive Phase III
- ❌ **BYND** (2026-09-23) drop:-15.5% → Day23:-32.3% [-] conf:78% Beyond Meat suffered a massive legal set
- ❌ **WGS** (2026-09-23) drop:-12.8% → Day23:-26.0% [-] conf:72% Market is pricing in regulatory risk and
- ✅ **BSP** (2026-09-23) drop:-10.4% → Day23:+34.9% [-] conf:72% 市场将BSP的-10.45%暴跌归因为隐含的重大负面事件（如‘3 warning
- ❌ **GEN** (2026-09-23) drop:-9.1% → Day23:-9.2% [-] conf:72% GEN sold off sharply alongside broader m
- ✅ **ABNB** (2026-09-23) drop:-9.7% → Day23:+15.1% [-] conf:72% Meta’s AI agent Muse threatens to disint
- ❌ **RUM** (2026-09-23) drop:-8.6% → Day23:-31.6% [-] conf:72% Market conflates RUM with Trump Media an
- ❌ **TTD** (2026-09-23) drop:-8.5% → Day23:-3.6% [-] conf:72% 市场将TTD的-8.5%下跌归因为‘指数剔除引发的机械抛压+AI竞争加剧导致基本
- ❌ **NKTR** (2026-09-23) drop:-13.7% → Day23:-37.7% [-] conf:78% NKTR stock collapsed on fears that an ad
- ✅ **LFTO** (2026-09-23) drop:-8.8% → Day23:+2.5% [-] conf:62% 市场将 Piper Sandler 的 Neutral initiation w
- ❌ **CARG** (2026-09-23) drop:-7.8% → Day23:-1.8% [-] conf:72% Meta's Muse AI assistant threatens CarGu
- ❌ **ACAD** (2026-09-24) drop:-13.2% → Day22:-13.2% [-] conf:78% Remlifanserin Phase 2 RADIANT study narr
- ❌ **VKTX** (2026-09-24) drop:-12.8% → Day22:-30.8% [-] conf:78% 市场将VKTX的$500M concurrent equity + conver
- ✅ **FSLR** (2026-09-24) drop:-10.9% → Day22:+1.5% [-] conf:72% Solar stocks collapsed due to rising bor
- ❌ **SNX** (2026-09-24) drop:-10.3% → Day22:-4.8% [-] conf:78% Market punished SNX despite strong Q3 EP
- ❌ **BYND** (2026-09-24) drop:-9.5% → Day22:-24.9% [-] conf:78% Beyond Meat agreed to exchange $15M of 0
- ❌ **AUR** (2026-09-24) drop:-5.1% → Day22:-18.0% [-] conf:72% Market interpreted Aurora's ambitious 30
- ✅ **GEN** (2026-09-24) drop:-12.1% → Day22:+4.3% [-] conf:58% Gen Digital’s stock plunged on news it m
- ✅ **ZS** (2026-09-25) drop:-9.3% → Day21:+6.8% [-] conf:78% Market interprets CRO leadership change
- ❌ **TWLO** (2026-09-25) drop:-8.1% → Day21:-11.9% [-] conf:68% Twilio's rally on Meta's Muse AI integra
- ❌ **BYND** (2026-09-25) drop:-8.5% → Day21:-18.8% [-] conf:78% Market interpreted the US judge's reduct
- ❌ **ACAD** (2026-09-25) drop:-6.6% → Day21:-7.5% [-] conf:72% Remlifanserin failed its Phase 2 primary
- ❌ **VCYT** (2026-09-25) drop:-6.2% → Day21:-5.3% [-] conf:72% Market is punishing VCYT on unconfirmed
- ❌ **OCUL** (2026-09-28) drop:-18.6% → Day18:-11.6% [-] conf:78% OCUL’s -18.6% crash is driven by perceiv
- ❌ **MDB** (2026-09-28) drop:-16.6% → Day18:-1.6% [-] conf:78% CEO abrupt departure to Meta signals lea
- ❌ **AUR** (2026-09-28) drop:-10.8% → Day18:-8.7% [-] conf:72% 市场因缺乏明确负面催化剂而恐慌性抛售，将高增长叙事下的估值脆弱性误读为基本面恶化
- ❌ **ARM** (2026-09-28) drop:-8.3% → Day18:-19.6% [-] conf:72% Arm is collapsing due to broad-based sem
- ❌ **WRBY** (2026-09-28) drop:-6.4% → Day18:-5.9% [-] conf:72% Market is punishing WRBY as part of a br
- ✅ **RBLX** (2026-09-28) drop:-7.8% → Day18:+15.4% [-] conf:62% Jefferies downgraded RBLX to Underperfor
- ❌ **FLUT** (2026-09-28) drop:-7.5% → Day18:-2.2% [-] conf:78% Market interprets Flutter's SEC 8-K fili
- ✅ **VEON** (2026-09-28) drop:-6.0% → Day18:+21.1% [-] conf:78% VEON is being lumped with weak telecom m
- ✅ **TEO** (2026-09-28) drop:-7.2% → Day18:+3.4% [-] conf:72% Insider exit (CFO resignation) signals d
- ❌ **QURE** (2026-09-29) drop:-36.7% → Day17:-11.1% [-] conf:78% 市场将48个月Huntington病长期数据解读为'clinical plate
- ✅ **FICO** (2026-09-29) drop:-27.6% → Day17:+26.0% [-] conf:78% FHFA新规废除FICO在房贷定价中的独家优势，VantageScore获得同等
- ❌ **WGS** (2026-09-29) drop:-11.4% → Day17:-17.1% [-] conf:78% Short-seller attack triggered panic sell
- ✅ **SRAD** (2026-09-29) drop:-6.5% → Day17:+1.7% [-] conf:68% Market is selling off SRAD on vague 'val
- ✅ **FA** (2026-09-29) drop:-5.2% → Day17:+9.4% [-] conf:72% 市场因缺乏明确负面催化剂而对FA进行无差别抛售，可能受流动性扰动或算法交易驱动，
- ✅ **LQDA** (2026-09-30) drop:-53.9% → Day16:+6.0% [-] conf:74% Liquidia lost a patent infringement case
- ❌ **TRLV** (2026-09-30) drop:-15.5% → Day16:-5.1% [-] conf:78% DEA chief judge paused the cannabis resc
- ❌ **JBL** (2026-09-30) drop:-10.2% → Day16:-2.8% [-] conf:78% Despite strong AI-driven earnings beat a
- ❌ **CBRS** (2026-09-30) drop:-8.4% → Day16:-28.7% [-] conf:72% Market is pricing in structural weakness
- ❌ **SLNHP** (2026-09-30) drop:-5.2% → Day16:-14.0% [-] conf:72% 市场因一份未披露实质内容的SEC 8-K文件而恐慌性抛售，隐含叙事为‘突发重大不
- ❌ **TIGO** (2026-09-30) drop:-5.0% → Day16:-5.6% [-] conf:78% 市场将TIGO（Millicom）与Tigo Energy（TYGO）混淆，误读
- ✅ **CTVA** (2026-10-01) drop:-84.3% → Day15:+4.9% [-] conf:82% CTVA collapsed because it 'lost' its hig
- ❌ **NKTR** (2026-10-01) drop:-21.9% → Day15:-24.0% [-] conf:78% Market interpreted positive EADV data on
- ✅ **LQDA** (2026-10-01) drop:-11.4% → Day15:+29.0% [-] conf:78% Liquidia lost a pivotal patent infringem
- ❌ **GRND** (2026-10-01) drop:-7.6% → Day15:-1.1% [-] conf:78% Market interpreted the $250M Freddie acq
- ❌ **PSKY** (2026-10-01) drop:-8.6% → Day15:+nan% [-] conf:78% Market is punishing PSKY for issuing $52
- ✅ **TEO** (2026-10-01) drop:-5.2% → Day15:+7.4% [-] conf:72% Market perceives TEO as vulnerable to Ar
- ❌ **SLS** (2026-10-01) drop:-8.0% → Day15:-12.3% [-] conf:68% 市场将SLS近期AML临床进展延迟与不确定性解读为管线实质性退步，叠加高估值（3
- ❌ **WDC** (2026-10-02) drop:-10.2% → Day14:-19.4% [-] conf:72% Toshiba’s announced HDD production expan
- ❌ **STX** (2026-10-02) drop:-10.0% → Day14:-24.7% [-] conf:72% Toshiba计划在2027财年将AI数据中心用HDD产能翻倍，将加剧价格战、侵
- ❌ **ADRX** (2026-10-02) drop:-7.8% → Day14:-1.7% [-] conf:78% 市场将IPO超额配售（绿鞋）行权解读为负面信号，暗示公司急于套现、估值过高或需求
- ❌ **NKTR** (2026-10-02) drop:-6.6% → Day14:-18.1% [-] conf:78% Despite strong long-term alopecia durabi
- ✅ **CTVA** (2026-10-02) drop:-5.2% → Day14:+7.5% [-] conf:78% Corteva’s -5.17% drop reflects panic ove
- ❌ **PGEN** (2026-10-05) drop:-10.5% → Day11:-16.9% [-] conf:72% 市场将PGEN与Novo的Denecimig BLA延迟事件错误关联，误读为PG
- ❌ **SRRK** (2026-10-05) drop:-8.9% → Day11:-6.2% [-] conf:78% Market interpreted FDA-related news as a
- ❌ **ACMR** (2026-10-05) drop:-8.9% → Day11:-29.8% [-] conf:74% ACMR跌超9%是因地缘政治担忧（尤其涉华供应链风险）引发的‘中国暴露’恐慌，市
- ❌ **UMC** (2026-10-05) drop:-8.8% → Day11:-17.3% [-] conf:78% UMC’s 8.77% drop is driven by negative m
- ❌ **SLNHP** (2026-10-05) drop:-7.9% → Day11:-3.6% [-] conf:72% 市场因不明负面事件或流动性枯竭对SLNHP进行抛售，隐含叙事为‘基本面恶化’或‘
- ❌ **TWST** (2026-10-06) drop:-17.6% → Day10:-21.3% [-] conf:72% Cathie Wood’s ARK sold $18M of TWST shar
- ❌ **TEM** (2026-10-06) drop:-13.8% → Day10:-11.2% [-] conf:74% 市场将FDA 510(k) clearance解读为‘peak news’或 ‘
- ❌ **STX** (2026-10-06) drop:-9.6% → Day10:-20.1% [-] conf:72% Toshiba's HDD capacity expansion trigger
- ❌ **TWLO** (2026-10-06) drop:-7.3% → Day10:-13.0% [-] conf:78% Twilio was downgraded in index membershi
- ❌ **WDC** (2026-10-06) drop:-6.9% → Day10:-18.5% [-] conf:72% Toshiba’s HDD capacity expansion threate
- ❌ **CELC** (2026-10-07) drop:-7.3% → Day9:-15.5% [-] conf:58% 市场因不明原因抛售CELC，唯一可见信号是某只2027年1月到期的虚值认沽期权（
- ✅ **FMS** (2026-10-07) drop:-7.0% → Day9:+6.3% [-] conf:74% Market is pricing in CEO transition as a
- ❌ **INFQ** (2026-10-07) drop:-7.5% → Day9:-26.6% [-] conf:78% 市场将INFQ的-7.5%下跌错误归因为负面事件，实则无实质性利空；叙事源于‘量
- ❌ **DIOD** (2026-10-07) drop:-7.5% → Day9:-16.4% [-] conf:72% Market is punishing DIOD on a 'surprise
- ❌ **CW** (2026-10-07) drop:-8.7% → Day9:-0.7% [-] conf:78% Market is pricing in leadership vacuum a
- ❌ **NBIS** (2026-10-07) drop:-5.5% → Day9:-30.4% [-] conf:72% NBIS sold off on broad risk-off sentimen
- ❌ **SBET** (2026-10-07) drop:-5.4% → Day9:-15.7% [-] conf:72% Market is conflating SBET with unrelated
- ❌ **RXRX** (2026-10-07) drop:-7.8% → Day9:-18.4% [-] conf:62% 市场将RXRX的-7.78%单日下跌解读为负面信号，暗示潜在基本面恶化或资金撤离
- ❌ **BB** (2026-10-07) drop:-8.5% → Day9:-8.2% [-] conf:78% 市场将CEO $1.38M股份减持解读为公司基本面恶化的负面信号，叠加短期技术面
- ❌ **AAOI** (2026-10-08) drop:-13.4% → Day8:-28.1% [-] conf:78% Optics sector-wide profit-taking after o
- ❌ **ARGX** (2026-10-08) drop:-11.3% → Day8:-0.2% [-] conf:78% ARGX halted its Phase 3 UNITY trial for
- ❌ **MXL** (2026-10-08) drop:-11.3% → Day8:-25.6% [-] conf:72% Market is pricing in AI infrastructure s
- ❌ **RUM** (2026-10-08) drop:-8.3% → Day8:-16.8% [-] conf:62% Market is pricing in skepticism toward L
- ❌ **NBIS** (2026-10-08) drop:-7.8% → Day8:-24.8% [-] conf:78% NBIS sold off alongside broader rate-dri
- ❌ **RXRX** (2026-10-08) drop:-8.6% → Day8:-10.6% [-] conf:72% Market is punishing RXRX for insider sel
- ❌ **DPC** (2026-10-08) drop:-5.7% → Day8:-20.6% [-] conf:78% 市场将DPC Holdings PLC与Bridgestone高尔夫球杆新闻错误
- ✅ **TMUS** (2026-10-09) drop:-12.7% → Day7:+6.0% [-] conf:78% SpaceX’s $8B low-band spectrum acquisiti
- ✅ **T** (2026-10-09) drop:-11.0% → Day7:+6.1% [-] conf:78% AT&T is structurally threatened by Space
- ✅ **HPQ** (2026-10-09) drop:-7.6% → Day7:+0.1% [-] conf:72% HPQ is suffering a sharp, unexplained se
- ❌ **BKD** (2026-10-09) drop:-5.9% → Day7:-2.2% [-] conf:72% Market interpreted BKD's September occup
- ✅ **FICO** (2026-10-09) drop:-5.8% → Day7:+15.1% [-] conf:72% Market is pricing in structural deterior
- ❌ **MOS** (2026-10-09) drop:-5.0% → Day7:-0.0% [-] conf:62% RBC downgraded MOS citing Belarus potash
- ❌ **CIEN** (2026-10-12) drop:-10.6% → Day4:-16.9% [-] conf:72% 市场将CIEN的-10.6%单日暴跌归因为AI infrastructure w
- ❌ **RXRX** (2026-10-12) drop:-8.7% → Day4:-12.4% [-] conf:72% 市场在无明确负面催化剂下抛售 RXRX despite pre-market s
- ❌ **LITE** (2026-10-12) drop:-10.3% → Day4:-16.1% [-] conf:72% Lumentum plunged -10.3% amid broad AI st
- ❌ **LCID** (2026-10-12) drop:-9.4% → Day4:-8.3% [-] conf:62% Lucid is collapsing due to deteriorating
- ✅ **BLCO** (2026-10-12) drop:-7.4% → Day4:+2.2% [-] conf:74% CEO sudden departure + interim leadershi
- ❌ **NBIS** (2026-10-12) drop:-5.4% → Day4:-21.4% [-] conf:62% AI infrastructure bubble is deflating; N
- ❌ **LUMN** (2026-10-12) drop:-5.0% → Day4:-8.9% [-] conf:52% Market is pricing in undisclosed negativ
- ❌ **DPC** (2026-10-12) drop:-6.0% → Day4:-16.0% [-] conf:78% 市场将DPC出售Ivostud（非核心工业部件业务）解读为公司战略收缩、增长乏力
- ❌ **CBRS** (2026-10-12) drop:-10.7% → Day4:-13.1% [-] conf:62% CBRS plunged on a negative report sugges
- ✅ **VERA** (2026-10-12) drop:-7.2% → Day4:+1.0% [-] conf:68% 市场将 Leerink 的 Market Perform 首次覆盖误读为负面信号
- ❌ **BYND** (2026-10-12) drop:-5.1% → Day4:-6.7% [-] conf:62% 市场将Beyond Meat与近期食品板块波动、AI-driven sector
- ❌ **PDFS** (2026-10-13) drop:-10.3% → Day3:-17.0% [-] conf:78% Market is conflating PDFS with a critica
- ❌ **SMMT** (2026-10-13) drop:-8.4% → Day3:-6.3% [-] conf:62% Market is pricing in unexplained, broad-
- ❌ **DPC** (2026-10-13) drop:-7.1% → Day3:-8.3% [-] conf:78% Market interpreted the Ivostud divestitu
- ❌ **AMAT** (2026-10-13) drop:-7.1% → Day3:-11.3% [-] conf:72% Applied Materials declined 7% because it
- ❌ **KOD** (2026-10-13) drop:-7.5% → Day3:-6.3% [-] conf:72% 市场将KOD与OCUL、FDMT等湿性AMD竞品进展负面消息错误关联，形成‘AM
- ✅ **GTLB** (2026-10-13) drop:-7.2% → Day3:+0.9% [-] conf:68% 市场因不明原因抛售GitLab，尽管当日无负面基本面事件、板块持平、且多篇报道强
- ❌ **AUR** (2026-10-13) drop:-5.7% → Day3:-7.9% [-] conf:62% 市场因不明负面事件或 liquidity-driven panic 抛售AUR,
- ❌ **PL** (2026-10-13) drop:-5.0% → Day3:-11.2% [-] conf:72% Market is pricing in continued deteriora
- ❌ **SKYD** (2026-10-14) drop:-26.3% → Day2:-0.1% [-] conf:78% Skydance issued 471M warrants at $12 (we
- ❌ **CRWV** (2026-10-14) drop:-15.9% → Day2:-7.6% [-] conf:68% CoreWeave plunged due to macro-driven AI
- ✅ **KOD** (2026-10-14) drop:-10.2% → Day2:+4.5% [-] conf:62% Market is pricing in undisclosed negativ
- ❌ **DOCN** (2026-10-14) drop:-14.1% → Day2:-11.6% [-] conf:78% DOCN sold off sharply as part of a broad
- ✅ **MMED** (2026-10-14) drop:-8.1% → Day2:+5.6% [-] conf:78% Market interpreted Medtronic's announcem
- ❌ **NBIS** (2026-10-14) drop:-10.9% → Day2:-10.8% [-] conf:68% Nebius is being punished as part of a br
- ✅ **BYND** (2026-10-14) drop:-6.8% → Day2:+1.5% [-] conf:72% 市场将弱盈利展望（未披露细节） as a fundamental deterio
- ❌ **HOOD** (2026-10-14) drop:-8.7% → Day2:-2.7% [-] conf:72% Market is pricing in near-term earnings
- ❌ **AUR** (2026-10-14) drop:-6.4% → Day2:-1.6% [-] conf:62% Market is pricing in deteriorating funda
- ❌ **VRT** (2026-10-14) drop:-6.3% → Day2:-6.8% [-] conf:72% Market is pricing in relative underperfo
- ❌ **PL** (2026-10-14) drop:-6.2% → Day2:-5.3% [-] conf:78% Planet Labs is being punished by associa
- ❌ **LCID** (2026-10-14) drop:-6.0% → Day2:-0.2% [-] conf:58% Lucid is collapsing due to existential d
- ❌ **COIN** (2026-10-14) drop:-5.4% → Day2:-0.5% [-] conf:72% Coinbase is overreacting to speculative,
- ❌ **SLNHP** (2026-10-14) drop:-8.7% → Day2:-0.5% [-] conf:78% 市场将SLNHP视为高贝塔小盘金融股，在SPY-1.1%、XLF-0.6%的宏观
**Accuracy: 275/609 (45%)**
### CORRECT (15 signals)
- ✅ **IONS** (2026-07-09) drop:-23.4% → Day29:-12.9% [-] conf:92% Ionis/AZ's eplontersen failed Phase 3 in
- ❌ **RGTIW** (2026-07-13) drop:-18.8% → Day30:+31.4% [-] conf:92% Rigetti plunged alongside other speculat
- ❌ **RGTIW** (2026-07-14) drop:-7.5% → Day30:+19.2% [-] conf:92% 量子计算板块遭遇系统性风险出清，Rigetti被连带抛售，市场将其与IonQ、D
- ❌ **NFLX** (2026-07-17) drop:-7.3% → Day28:+13.3% [-] conf:87% Netflix beat EPS but cut Q3 revenue grow
- ❌ **TSLA** (2026-07-23) drop:-14.4% → Day29:+14.1% [-] conf:87% Tesla missed Q2 2026 EPS and auto margin
- ❌ **COIN** (2026-07-31) drop:-8.0% → Day28:+19.1% [-] conf:92% COIN stock crashed due to Q2 earnings mi
- ✅ **LMAT** (2026-08-05) drop:-22.9% → Day30:-0.7% [-] conf:87% LMAT Q2 EPS miss (-6.3%) and meaningful
- ✅ **LCID** (2026-08-05) drop:-15.1% → Day30:-29.9% [-] conf:87% Lucid missed Q2 expectations and slashed
- ❌ **FLUT** (2026-08-05) drop:-14.2% → Day30:+11.9% [-] conf:87% Flutter missed Q2 EPS by 18% ($0.49 vs $
- ❌ **BYND** (2026-08-11) drop:-21.1% → Day30:+2465.8% [-] conf:92% Beyond Meat’s 1-for-30 reverse stock spl
- ❌ **DJT** (2026-08-12) drop:-6.7% → Day30:+4.8% [-] conf:87% DJT’s Q2 revenue growth (89% y/y) is ove
- ❌ **ZBIO** (2026-08-13) drop:-8.7% → Day29:+10.3% [-] conf:87% ZBIO missed Q2 EPS by 64% and revenue by
- ✅ **DJT** (2026-09-01) drop:-7.1% → Day30:-2.8% [-] conf:82% Trump Media sold off alongside broader r
- ✅ **LCID** (2026-10-07) drop:-6.1% → Day9:-19.4% [-] conf:87% Lucid’s Q3 delivery miss (2,954 units, -
- ✅ **IMNM** (2026-10-13) drop:-8.2% → Day3:-6.0% [-] conf:92% IMNM跌8.2%是受生物技术板块整体疲软拖累，尤其XLV下跌1.4%，市场未针
**Accuracy: 6/15 (40%)**
### UNCLEAR (16 signals)
- ❓ **RGC** (2026-07-06) drop:-7.8% → Day30:+0.5% [-] conf:52% 市场将DOJ监管调查解读为实质性业务风险与估值崩溃信号，叠加短期做空情绪与流动性
- ❓ **NAMSW** (2026-07-20) drop:-11.5% → Day30:+nan% [-] conf:42% 市场因不明负面事件抛售NAMSW，但无公开信息支撑，形成真空式恐慌。
- ❓ **BDRX** (2026-07-21) drop:-16.9% → Day30:-26.6% [-] conf:42% 市场因不明负面事件抛售BDRX, 暗示存在未披露的重大风险或 pipeline
- ❓ **SLBT** (2026-07-22) drop:-9.3% → Day30:-22.3% [-] conf:42% 市场因不明负面事件抛售SLBT, 暗示存在未披露的重大风险（如临床失败、FDA警
- ❓ **DPC** (2026-07-28) drop:-5.7% → Day30:-0.3% [-] conf:42% 市场因不明负面消息或 liquidity-driven panic 抛售 DPC
- ❓ **NAMSW** (2026-07-28) drop:-12.8% → Day30:+nan% [-] conf:42% 市场因不明负面事件或 liquidity-driven panic sellin
- ❓ **NAMSW** (2026-08-17) drop:-8.1% → Day30:+nan% [-] conf:42% 市场因不明负面事件（可能与SEC 8-K披露有关）抛售NAMSW, 暗示监管风险
- ❓ **AAOI** (2026-08-24) drop:-11.5% → Day30:-8.3% [-] conf:0%
- ❓ **VISN** (2026-08-28) drop:-47.2% → Day28:+1.7% [-] conf:42% VISN suffered a catastrophic intraday co
- ❓ **SLNHP** (2026-09-14) drop:-5.2% → Day30:+nan% [-] conf:42% 市场因不明负面事件（疑似突发监管披露）抛售SLNHP, 暗示公司治理、合规或 c
- ❓ **GENVR** (2026-09-16) drop:-5.3% → Day30:-76.8% [-] conf:42% Gen Digital stock declined amid broad AI
- ❓ **SRAD** (2026-09-17) drop:-5.9% → Day29:-4.8% [-] conf:52% Market perceives SRAD's stock slump as e
- ❓ **FA** (2026-09-28) drop:-5.0% → Day18:+3.7% [-] conf:0%
- ❓ **SLNHP** (2026-10-01) drop:-7.0% → Day15:-12.9% [-] conf:42% 市场将SEC 8-K文件解读为重大负面监管事件，暗示公司可能面临调查、内控缺陷或
- ❓ **PL** (2026-10-12) drop:-6.8% → Day4:-15.8% [-] conf:42% Planet Labs is losing altitude in the 's
- ❓ **SMTC** (2026-10-12) drop:-10.2% → Day4:-18.9% [-] conf:0%
## Missed Opportunities
These were NOT flagged as MISJUDGMENT but recovered significantly:
- **RGTIW** judged CORRECT → Day30:+31.4% (Rigetti plunged alongside other speculat)
- **RGTIW** judged CORRECT → Day30:+19.2% (量子计算板块遭遇系统性风险出清，Rigetti被连带抛售，市场将其与IonQ、D)
- **NFLX** judged CORRECT → Day28:+13.3% (Netflix beat EPS but cut Q3 revenue grow)
- **TSLA** judged CORRECT → Day29:+14.1% (Tesla missed Q2 2026 EPS and auto margin)
- **COIN** judged CORRECT → Day28:+19.1% (COIN stock crashed due to Q2 earnings mi)
- **FLUT** judged CORRECT → Day30:+11.9% (Flutter missed Q2 EPS by 18% ($0.49 vs $)
- **BYND** judged CORRECT → Day30:+2465.8% (Beyond Meat’s 1-for-30 reverse stock spl)
- **ZBIO** judged CORRECT → Day29:+10.3% (ZBIO missed Q2 EPS by 64% and revenue by)